Efficacy and risk profile of anti-diabetic therapies: Conventional vs traditional drugs—A mechanistic revisit to understand their mode of action

Pharmacological Research

Volumn 113, Issue , 2016, Pages 636-674

  Gupta, Prachi ^a   Bala, Manju ^a   Gupta, Sanjeev ^a   Dua, Anita ^a   Dabur, Rajesh ^b   Injeti, Elisha ^c   Mittal, Ashwani ^a  

^a KURUKSHETRA UNIVERSITY   (India)

^b MAHARSHI DAYANAND UNIVERSITY   (India)

^c CEDARVILLE UNIVERSITY   (United States)

Author keywords

Anti diabetic drugs; Dipeptidyl peptidase 4 inhibitors; Metformin; miRNAs; Phyto drugs; SGLT2; Sulfonylureas; Thiazolidinediones; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; CINNAMON EXTRACT; GINSENG EXTRACT; GLUCOSE; INCRETIN; INSULIN SENSITIZING AGENT; INTERLEUKIN 10; INTERLEUKIN 6; MEGLITINIDE; PLANT MEDICINAL PRODUCT; RESVERATROL; TUMOR NECROSIS FACTOR;

ANTIDIABETIC ACTIVITY; CINNAMON; CYTOKINE PRODUCTION; DIABETES MELLITUS; DRUG EFFICACY; DRUG MECHANISM; FENUGREEK; GINSENG; GLUCOSE BLOOD LEVEL; HUMAN; INTRACELLULAR SIGNALING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; RISK BENEFIT ANALYSIS; TINOSPORA CORDIFOLIA; ANIMAL; DISEASE MANAGEMENT; DRUG EFFECTS; RISK; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; HUMANS; HYPOGLYCEMIC AGENTS; RISK; SIGNAL TRANSDUCTION;

EID: 84992458888     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.09.029     Document Type: Review

References (458)

1. [1] Kaveeshwar, S.A., Cornwall, J., The current state of diabetes mellitus in India. Aust. Med. J. 7 (2014), 45–48.
2. [2] Whiting, D.R., Guariguata, L., Weil, C., Shaw, J., IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res. Clin. Pract. 94 (2011), 311–321.
3. [3] Diabetes Atlas IDF 2015 (2015).
4. [4] Campbell-Tofte, J., Mølgaard, Per., Winther, Kaj, Harnessing the potential clinical use of medicinal plants as anti-diabetic agents. Botanics: Targets Therapy, 2, 2012, 7.
5. [5] Buchanan, T.A., Xiang, A., Kjos, S.L., Watanabe, R., What is gestational diabetes?. Diabetes Care 30:Suppl. 2 (2007), S105–S111.
6. [6] Soumya, D., Srilatha, B., Late stage complications of diabetes and insulin resistance. J. Diabetes Metab., 02, 2011.
7. [7] Cade, W.T., Diabetes-related microvascular and macrovascular diseases in the physical therapy setting. Phys. Ther. 88 (2008), 1322–1335.
8. [8] Musi, N., Hirshman, M.F., Nygren, J., Svanfeldt, M., Bavenholm, P., Rooyackers, O., Zhou, G., Williamson, J.M., Ljunqvist, O., Efendic, S., Moller, D.E., Thorell, A., Goodyear, L.J., Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. Diabetes 51 (2002), 2074–2081.
9. [9] Mackenzie, R.W., Elliott, B.T., Akt/PKB activation and insulin signaling: a novel insulin signaling pathway in the treatment of type 2 diabetes. Diabetes Metab. Syndrome Obesity: Targets Therapy 7 (2014), 55–64.
10. [10] Bösenberg, L.H., van Zyl, D.G., The mechanism of action of oral antidiabetic drugs: a review of recent literature. Journal of Endocrinology. Metab. Diabetes South Afr. 13 (2008), 80–88.
11. [11] Qaseem, A., Humphrey, L.L., Sweet, D.E., Starkey, M., Shekelle, P., Clinical Guidelines Committee of the American College of oral pharmacologic treatment of type 2 diabetes mellitus: a clinical practice guideline from the American College of Physicians. Ann. Intern. Med. 156 (2012), 218–231.
12. [12] Inzucchi, S.E., Bergenstal, R.M., Buse, J.B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A.L., Tsapas, A., Wender, R., Matthews, D.R., Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38 (2015), 140–149.
13. [13] Nattrass, M., Alberti, K.G., Biguanides. Diabetologia 14 (1978), 71–74.
14. [14] Shaw, R.J., Lamia, K.A., Vasquez, D., Koo, S.H., Bardeesy, N., Depinho, R.A., Montminy, M., Cantley, L.C., The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310 (2005), 1642–1646.
15. [15] Bridges, H.R., Jones, A.J., Pollak, M.N., Hirst, J., Effects of metformin and other biguanides on oxidative phosphorylation in mitochondria. Biochem. J. 462 (2014), 475–487.
16. [16] Pollak, M.N., Investigating metformin for cancer prevention and treatment: the end of the beginning. Cancer Discov. 2 (2012), 778–790.
17. [17] Pernicova, I., Korbonits, M., Metformin–mode of action and clinical implications for diabetes and cancer. Nat. Rev. Endocrinol. 10 (2014), 143–156.
18. [18] Yin, M., van der Horst, I.C., van Melle, J.P., Qian, C., van Gilst, W.H., Sillje, H.H., de Boer, R.A., Metformin improves cardiac function in a nondiabetic rat model of post-MI heart failure. Am. J. Physiol. Heart Circ. Physiol. 301 (2011), H459–468.
19. [19] Owen, M.R., Doran, E., Halestrap, A.P., Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348:Pt. 3 (2000), 607–614.
20. [20] Zou, M.H., Kirkpatrick, S.S., Davis, B.J., Nelson, J.S., Wiles, W.G.t., Schlattner, U., Neumann, D., Brownlee, M., Freeman, M.B., Goldman, M.H., Activation of the AMP-activated protein kinase by the anti-diabetic drug metformin in vivo. Role of mitochondrial reactive nitrogen species. J. Biol. Chem. 279 (2004), 43940–43951.
21. [21] Kahn, B.B., Alquier, T., Carling, D., Hardie, D.G., AMP-activated protein kinase: ancient energy gauge provides clues to modern understanding of metabolism. Cell Metab. 1 (2005), 15–25.
22. [22] Hardie, D.G., Ross, F.A., Hawley, S.A., AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat. Rev. Mol. Cell Biol. 13 (2012), 251–262.
23. [23] Carling, D., Thornton, C., Woods, A., Sanders, M.J., AMP-activated protein kinase: new regulation, new roles?. Biochem. J. 445 (2012), 11–27.
24. [24] Viollet, B., Guigas, B., Leclerc, J., Hebrard, S., Lantier, L., Mounier, R., Andreelli, F., Foretz, M., AMP-activated protein kinase in the regulation of hepatic energy metabolism: from physiology to therapeutic perspectives. Acta Physiol. 196 (2009), 81–98.
25. [25] Phielix, E., Szendroedi, J., Roden, M., The role of metformin and thiazolidinediones in the regulation of hepatic glucose metabolism and its clinical impact. Trends Pharmacol. Sci. 32 (2011), 607–616.
26. [26] Herzig, S., Long, F., Jhala, U.S., Hedrick, S., Quinn, R., Bauer, A., Rudolph, D., Schutz, G., Yoon, C., Puigserver, P., Spiegelman, B., Montminy, M., CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 413 (2001), 179–183.
27. [27] Koo, S.H., Satoh, H., Herzig, S., Lee, C.H., Hedrick, S., Kulkarni, R., Evans, R.M., Olefsky, J., Montminy, M., PGC-1 promotes insulin resistance in liver through PPAR-alpha-dependent induction of TRB-3. Nat. Med. 10 (2004), 530–534.
28. [28] Viollet, B., Foretz, M., Revisiting the mechanisms of metformin action in the liver. Annales d'endocrinologie 74 (2013), 123–129.
29. [29] Caton, P.W., Nayuni, N.K., Kieswich, J., Khan, N.Q., Yaqoob, M.M., Corder, R., Metformin suppresses hepatic gluconeogenesis through induction of SIRT1 and GCN5. J. Endocrinol. 205 (2010), 97–106.
30. [30] Lerin, C., Rodgers, J.T., Kalume, D.E., Kim, S.H., Pandey, A., Puigserver, P., GCN5 acetyltransferase complex controls glucose metabolism through transcriptional repression of PGC-1alpha. Cell Metab. 3 (2006), 429–438.
31. [31] Hou, X., Xu, S., Maitland-Toolan, K.A., Sato, K., Jiang, B., Ido, Y., Lan, F., Walsh, K., Wierzbicki, M., Verbeuren, T.J., Cohen, R.A., Zang, M., SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J. Biol. Chem. 283 (2008), 20015–20026.
32. [32] Aatsinki, S.M., Buler, M., Salomaki, H., Koulu, M., Pavek, P., Hakkola, J., Metformin induces PGC-1alpha expression and selectively affects hepatic PGC-1alpha functions. Br. J. Pharmacol. 171 (2014), 2351–2363.
33. [33] Foretz, M., Hebrard, S., Leclerc, J., Zarrinpashneh, E., Soty, M., Mithieux, G., Sakamoto, K., Andreelli, F., Viollet, B., Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J. Clin. Invest. 120 (2010), 2355–2369.
34. [34] Miller, R.A., Chu, Q., Xie, J., Foretz, M., Viollet, B., Birnbaum, M.J., Biguanides suppress hepatic glucagon signalling by decreasing production of cyclic AMP. Nature 494 (2013), 256–260.
35. [35] Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., Musi, N., Hirshman, M.F., Goodyear, L.J., Moller, D.E., Role of AMP-activated protein kinase in mechanism of metformin action. J. Clin. Invest. 108 (2001), 1167–1174.
36. [36] Foster, D.W., Malonyl-CoA: the regulator of fatty acid synthesis and oxidation. J. Clin. Invest. 122 (2012), 1958–1959.
37. [37] Ciaraldi, T.P., Mudaliar, S., Barzin, A., Macievic, J.A., Edelman, S.V., Park, K.S., Henry, R.R., Skeletal muscle GLUT1 transporter protein expression and basal leg glucose uptake are reduced in type 2 diabetes. J. Clin. Endocrinol. Metab. 90 (2005), 352–358.
38. [38] Kumar, N., Dey, C.S., Metformin enhances insulin signalling in insulin-dependent and-independent pathways in insulin resistant muscle cells. Br. J. Pharmacol. 137 (2002), 329–336.
39. [39] Alkhalaf F, S.A., De Sanctis, V., Metformin use in adolescents: old and new therapeutic perspectives. J. Diabetes Metab., 5, 2014.
40. [40] Holland, W., Morrison, T., Chang, Y., Wiernsperger, N., Stith, B.J., Metformin (Glucophage) inhibits tyrosine phosphatase activity to stimulate the insulin receptor tyrosine kinase. Biochem. Pharmacol. 67 (2004), 2081–2091.
41. [41] Kramer, H.F., Witczak, C.A., Taylor, E.B., Fujii, N., Hirshman, M.F., Goodyear, L.J., AS160 regulates insulin- and contraction-stimulated glucose uptake in mouse skeletal muscle. J. Biol. Chem. 281 (2006), 31478–31485.
42. [42] Elmadhun, N.Y., Lassaletta, A.D., Chu, L.M., Sellke, F.W., Metformin alters the insulin signaling pathway in ischemic cardiac tissue in a swine model of metabolic syndrome. J. Thoracic Cardiovasc. Surg. 145 (2013), 258–265 discussion 265–256.
43. [43] Canto, C., Auwerx, J., PGC-1alpha, SIRT1 and AMPK, an energy sensing network that controls energy expenditure. Curr. Opin. Lipidol. 20 (2009), 98–105.
44. [44] Joseph, A.M., Joanisse, D.R., Baillot, R.G., Hood, D.A., Mitochondrial dysregulation in the pathogenesis of diabetes: potential for mitochondrial biogenesis-mediated interventions. Exp. Diabetes Res., 2012, 2012, 642038.
45. [45] Finck, B.N., Kelly, D.P., PGC-1 coactivators: inducible regulators of energy metabolism in health and disease. J. Clin. Invest. 116 (2006), 615–622.
46. [46] Gleyzer, N., Vercauteren, K., Scarpulla, R.C., Control of mitochondrial transcription specificity factors (TFB1 M and TFB2 M) by nuclear respiratory factors (NRF-1 and NRF-2) and PGC-1 family coactivators. Mol. Cell. Biol. 25 (2005), 1354–1366.
47. [47] Al-Khalili, L., Forsgren, M., Kannisto, K., Zierath, J.R., Lonnqvist, F., Krook, A., Enhanced insulin-stimulated glycogen synthesis in response to insulin, metformin or rosiglitazone is associated with increased mRNA expression of GLUT4 and peroxisomal proliferator activator receptor gamma co-activator 1. Diabetologia 48 (2005), 1173–1179.
48. [48] Torres, T.P., Sasaki, N., Donahue, E.P., Lacy, B., Printz, R.L., Cherrington, A.D., Treadway, J.L., Shiota, M., Impact of a glycogen phosphorylase inhibitor and metformin on basal and glucagon-stimulated hepatic glucose flux in conscious dogs. J. Pharmacol. Exp. Ther. 337 (2011), 610–620.
49. [49] Wende, A.R., Schaeffer, P.J., Parker, G.J., Zechner, C., Han, D.H., Chen, M.M., Hancock, C.R., Lehman, J.J., Huss, J.M., McClain, D.A., Holloszy, J.O., Kelly, D.P., A role for the transcriptional coactivator PGC-1alpha in muscle refueling. J. Biol. Chem. 282 (2007), 36642–36665.
50. [50] Ruderman, N.B., Carling, D., Prentki, M., Cacicedo, J.M., AMPK, insulin resistance, and the metabolic syndrome. J. Clin. Invest. 123 (2013), 2764–2772.
51. [51] Park, D.R., Kim, J.S., Kim, C.K., The effect of SIRT1 protein knock down on PGC-1alpha acetylation during skeletal muscle contraction. J. Exercise Nutr. Biochem. 18 (2014), 1–7.
52. [52] Shoelson, S.E., Herrero, L., Naaz, A., Obesity, inflammation, and insulin resistance. Gastroenterology 132 (2007), 2169–2180.
53. [53] Qatanani, M., Lazar, M.A., Mechanisms of obesity-associated insulin resistance: many choices on the menu. Genes Dev. 21 (2007), 1443–1455.
54. [54] Hyun, B., Shin, S., Lee, A., Lee, S., Song, Y., Ha, N.J., Cho, K.H., Kim, K., Metformin down-regulates TNF-alpha secretion via suppression of scavenger receptors in macrophages. Immune Netw. 13 (2013), 123–132.
55. [55] Saba, L., Ikeda, N., Deidda, M., Araki, T., Molinari, F., Meiburger, K.M., Acharya, U.R., Nagashima, Y., Mercuro, G., Nakano, M., Nicolaides, A., Suri, J.S., Fellow, A., Association of automated carotid IMT measurement and HbA1c in Japanese patients with coronary artery disease. Diabetes Res. Clin. Pract. 100 (2013), 348–353.
56. [56] Sag, D., Carling, D., Stout, R.D., Suttles, J., Adenosine 5'-monophosphate-activated protein kinase promotes macrophage polarization to an anti-inflammatory functional phenotype. J. Immunol. 181 (2008), 8633–8864.
57. [57] Maida, A., Lamont, B.J., Cao, X., Drucker, D.J., Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-alpha in mice. Diabetologia 54 (2011), 339–349.
58. [58] Cho, Y.M., Kieffer, T.J., New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser. Diabetologia 54 (2011), 219–222.
59. [59] Lee, A.J., Metformin in noninsulin-dependent diabetes mellitus. Pharmacotherapy 16 (1996), 327–351.
60. [60] Price, G., Metformin lactic acidosis: acute renal failure and rofecoxib. Br. J. Anaesth. 91 (2003), 909–910.
61. [61] de Jager, J., Kooy, A., Lehert, P., Wulffele, M.G., van der Kolk, J., Bets, D., Verburg, J., Donker, A.J., Stehouwer, C.D., Long term treatment with metformin in patients with type 2 diabetes and risk of vitamin B-12 deficiency: randomised placebo controlled trial. BMJ, 340, 2010, c2181.
62. [62] Fujita, T., Sugiyama, Y., Taketomi, S., Sohda, T., Kawamatsu, Y., Iwatsuka, H., Suzuoki, Z., Reduction of insulin resistance in obese and/or diabetic animals by 5-[4-(1-methylcyclohexylmethoxy)benzyl]-thiazolidine-2, 4-dione (ADD-3878, U-63, 287, ciglitazone), a new antidiabetic agent. Diabetes 32 (1983), 804–810.
63. [63] T. Yokoi, Troglitazone Handbook of experimental pharmacology, pp. 419–435 (2010).
64. [64] Turner, L.W., Nartey, D., Stafford, R.S., Singh, S., Alexander, G.C., Ambulatory treatment of type 2 diabetes in the U.S., 1997–2012. Diabetes Care 37 (2014), 985–992.
65. [65] Soccio, R.E., Chen, E.R., Lazar, M.A., Thiazolidinediones and the promise of insulin sensitization in type 2 diabetes. Cell Metab. 20 (2014), 573–591.
66. [66] Kahn, C.R., Chen, L., Cohen, S.E., Unraveling the mechanism of action of thiazolidinediones. J. Clin. Invest. 106 (2000), 1305–1307.
67. [67] Kohlroser, J., Mathai, J., Reichheld, J., Banner, B.F., Bonkovsky, H.L., Hepatotoxicity due to troglitazone: report of two cases and review of adverse events reported to the United States Food and Drug Administration. Am. jJ. Gastroenterol. 95 (2000), 272–276.
68. [68] Lahiri, S.W., Management of type 2 diabetes: what is the next step after metformin?. Clin. Diabetes 30 (2012), 72–75.
69. [69] Tan, G.D., Fielding, B.A., Currie, J.M., Humphreys, S.M., Desage, M., Frayn, K.N., Laville, M., Vidal, H., Karpe, F., The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Diabetologia 48 (2005), 83–95.
70. [70] Sarafidis, P.A., Lasaridis, A.N., Nilsson, P.M., Mouslech, T.F., Hitoglou-Makedou, A.D., Stafylas, P.C., Kazakos, K.A., Yovos, J.G., Tourkantonis, A.A., The effect of rosiglitazone on novel atherosclerotic risk factors in patients with type 2 diabetes mellitus and hypertension. An open-label observational study. Metabolism 54 (2005), 1236–1242.
71. [71] Bodles, A.M., Varma, V., Yao-Borengasser, A., Phanavanh, B., Peterson, C.A., McGehee, R.E. Jr., Rasouli, N., Wabitsch, M., Kern, P.A., Pioglitazone induces apoptosis of macrophages in human adipose tissue. J. Lipid Res. 47 (2006), 2080–2088.
72. [72] Hueand, L., Taegtmeyer, H., The Randle cycle revisited: a new head for an old hat. Am. J. Physiol. Endocrinol. Metab. 297 (2009), E578–E591.
73. [73] Shulman, G.I., Cellular mechanisms of insulin resistance. J. Clin. Invest. 106 (2000), 171–176.
74. [74] Bajaj, M., Suraamornkul, S., Pratipanawatr, T., Hardies, L.J., Pratipanawatr, W., Glass, L., Cersosimo, E., Miyazaki, Y., DeFronzo, R.A., Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52 (2003), 1364–1370.
75. [75] Rasouli, N., Raue, U., Miles, L.M., Lu, T., Di Gregorio, G.B., Elbein, S.C., Kern, P.A., Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am. J. Physiol. Endocrinol. Metab. 288 (2005), E930–934.
76. [76] Saltiel, A.R., Olefsky, J.M., Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 45 (1996), 1661–1669.
77. [77] Berger, J., Moller, D.E., The mechanisms of action of PPARs. Annu. Rev. Med. 53 (2002), 409–435.
78. [78] Ferre, P., The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 53:Suppl. 1 (2004), S43–S50.
79. [79] Hartman, H.B., Hu, X., Tyler, K.X., Dalal, C.K., Lazar, M.A., Mechanisms regulating adipocyte expression of resistin. J. Biol. Chem. 277 (2002), 19754–19761.
80. [80] Banerjee, R.R., Lazar, M.A., Resistin: molecular history and prognosis. J. Mol. Med. 81 (2003), 218–226.
81. [81] Boden, G., Homko, C., Mozzoli, M., Showe, L.C., Nichols, C., Cheung, P., Thiazolidinediones upregulate fatty acid uptake and oxidation in adipose tissue of diabetic patients. Diabetes 54 (2005), 880–885.
82. [82] Grygiel-Gorniak, B., Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications–a review. Nutr. J., 13, 2014, 17.
83. [83] Hondares, E., Mora, O., Yubero, P., Rodriguez de la Concepcion, M., Iglesias, R., Giralt, M., Villarroya, F., Thiazolidinediones and rexinoids induce peroxisome proliferator-activated receptor-coactivator (PGC)-1alpha gene transcription: an autoregulatory loop controls PGC-1alpha expression in adipocytes via peroxisome proliferator-activated receptor-gamma coactivation. Endocrinology 147 (2006), 2829–2838.
84. [84] Weisberg, S.P., McCann, D., Desai, M., Rosenbaum, M., Leibel, R.L., Ferrante, A.W. Jr., Obesity is associated with macrophage accumulation in adipose tissue. J. Clin. Invest. 112 (2003), 1796–1808.
85. [85] Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., Ezaki, O., Akanuma, Y., Gavrilova, O., Vinson, C., Reitman, M.L., Kagechika, H., Shudo, K., Yoda, M., Nakano, Y., Tobe, K., Nagai, R., Kimura, S., Tomita, M., Froguel, P., Kadowaki, T., The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7 (2001), 941–946.
86. [86] Bouskila, M., Pajvani, U.B., Scherer, P.E., Adiponectin: a relevant player in PPARgamma-agonist-mediated improvements in hepatic insulin sensitivity?. Int. J. Obes. 29:Suppl. 1 (2005), S17–S23.
87. [87] Maeda, N., Takahashi, M., Funahashi, T., Kihara, S., Nishizawa, H., Kishida, K., Nagaretani, H., Matsuda, M., Komuro, R., Ouchi, N., Kuriyama, H., Hotta, K., Nakamura, T., Shimomura, I., Matsuzawa, Y., PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50 (2001), 2094–2099.
88. [88] Yamauchi, T., Kamon, J., Ito, Y., Tsuchida, A., Yokomizo, T., Kita, S., Sugiyama, T., Miyagishi, M., Hara, K., Tsunoda, M., Murakami, K., Ohteki, T., Uchida, S., Takekawa, S., Waki, H., Tsuno, N.H., Shibata, Y., Terauchi, Y., Froguel, P., Tobe, K., Koyasu, S., Taira, K., Kitamura, T., Shimizu, T., Nagai, R., Kadowaki, T., Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003), 762–769.
89. [89] Yamauchi, T., Kamon, J., Minokoshi, Y., Ito, Y., Waki, H., Uchida, S., Yamashita, S., Noda, M., Kita, S., Ueki, K., Eto, K., Akanuma, Y., Froguel, P., Foufelle, F., Ferre, P., Carling, D., Kimura, S., Nagai, R., Kahn, B.B., Kadowaki, T., Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 8 (2002), 1288–1295.
90. [90] Ceddia, R.B., Somwar, R., Maida, A., Fang, X., Bikopoulos, G., Sweeney, G., Globular adiponectin increases GLUT4 translocation and glucose uptake but reduces glycogen synthesis in rat skeletal muscle cells. Diabetologia 48 (2005), 132–139.
91. [91] Hevener, A.L., He, W., Barak, Y., Le, J., Bandyopadhyay, G., Olson, P., Wilkes, J., Evans, R.M., Olefsky, J., Muscle-specific Pparg deletion causes insulin resistance. Nat. Med. 9 (2003), 1491–1497.
92. [92] Amin, R.H., Mathews, S.T., Camp, H.S., Ding, L., Leff, T., Selective activation of PPARgamma in skeletal muscle induces endogenous production of adiponectin and protects mice from diet-induced insulin resistance. Am. J. Physiol. Endocrinol. Metab. 298 (2010), E28–37.
93. [93] Cho, M.C., Lee, D.H., Kim, E.J., Lee, J.Y., Kang, J.W., Song, J.H., Chong, Y., Kim, Y., Hong, J.T., Yoon, D.Y., Novel PPARgamma partial agonists with weak activity and no cytotoxicity; identified by a simple PPARgamma ligand screening system. Mol. Cell. Biochem. 358 (2011), 75–83.
94. [94] Chen, Z., Vigueira, P.A., Chambers, K.T., Hall, A.M., Mitra, M.S., Qi, N., McDonald, W.G., Colca, J.R., Kletzien, R.F., Finck, B.N., Insulin resistance and metabolic derangements in obese mice are ameliorated by a novel peroxisome proliferator-activated receptor gamma-sparing thiazolidinedione. J. Biol. Chem. 287 (2012), 23537–23548.
95. [95] Miles, P.D., Barak, Y., He, W., Evans, R.M., Olefsky, J.M., Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J. Clin. Invest. 105 (2000), 287–292.
96. [96] LaCivita, K.A., Villarreal, G., Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone. Curr. Med. Res. Opin. 18 (2002), 363–370.
97. [97] LeBrasseur, N.K., Kelly, M., Tsao, T.S., Farmer, S.R., Saha, A.K., Ruderman, N.B., Tomas, E., Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab. 291 (2006), E175–181.
98. [98] Colca, J.R., McDonald, W.G., Waldon, D.J., Leone, J.W., Lull, J.M., Bannow, C.A., Lund, E.T., Mathews, W.R., Identification of a novel mitochondrial protein (mitoNEET) cross-linked specifically by a thiazolidinedione photoprobe. Am. J. Physiol. Endocrinol. Metab. 286 (2004), E252–260.
99. [99] Brunmair, B., Staniek, K., Gras, F., Scharf, N., Althaym, A., Clara, R., Roden, M., Gnaiger, E., Nohl, H., Waldhausl, W., Furnsinn, C., Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 53 (2004), 1052–1059.
100. [100] Kumar, N., Dey, C.S., Development of insulin resistance and reversal by thiazolidinediones in C2C12 skeletal muscle cells. Biochem. Pharmacol. 65 (2003), 249–257.
101. [101] Miller, R.A., Chu, Q., Le Lay, J., Scherer, P.E., Ahima, R.S., Kaestner, K.H., Foretz, M., Viollet, B., Birnbaum, M.J., Adiponectin suppresses gluconeogenic gene expression in mouse hepatocytes independent of LKB1-AMPK signaling. J. Clin. Invest. 121 (2011), 2518–2528.
102. [102] Gastaldelli, A., Miyazaki, Y., Pettiti, M., Santini, E., Ciociaro, D., Defronzo, R.A., Ferrannini, E., The effect of rosiglitazone on the liver: decreased gluconeogenesis in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 91 (2006), 806–812.
103. [103] Yoon, Y.S., Ryu, D., Lee, M.W., Hong, S., Koo, S.H., Adiponectin and thiazolidinedione targets CRTC2 to regulate hepatic gluconeogenesis. Exp. Mol. Med. 41 (2009), 577–583.
104. [104] Holland, W.L., Miller, R.A., Wang, Z.V., Sun, K., Barth, B.M., Bui, H.H., Davis, K.E., Bikman, B.T., Halberg, N., Rutkowski, J.M., Wade, M.R., Tenorio, V.M., Kuo, M.S., Brozinick, J.T., Zhang, B.B., Birnbaum, M.J., Summers, S.A., Scherer, P.E., Receptor-mediated activation of ceramidase activity initiates the pleiotropic actions of adiponectin. Nat. Med. 17 (2011), 55–63.
105. [105] Sajan, M.P., Ivey, R.A., Lee, M.C., Farese, R.V., Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation. J. Lipid Res. 56 (2015), 70–80.
106. [106] Yang, G., Badeanlou, L., Bielawski, J., Roberts, A.J., Hannun, Y.A., Samad, F., Central role of ceramide biosynthesis in body weight regulation, energy metabolism, and the metabolic syndrome. Am. J. Physiol. Endocrinol. Metab. 297 (2009), E211–224.
107. [107] Wang, Y., Xu, A., Knight, C., Xu, L.Y., Cooper, G.J., Hydroxylation and glycosylation of the four conserved lysine residues in the collagenous domain of adiponectin. Potential role in the modulation of its insulin-sensitizing activity. J. Biol. Chem. 277 (2002), 19521–19529.
108. [108] Liu, Q., Yuan, B., Lo, K.A., Patterson, H.C., Sun, Y., Lodish, H.F., Adiponectin regulates expression of hepatic genes critical for glucose and lipid metabolism. Proc. Natl. Acad. Sci. U. S. A. 109 (2012), 14568–14573.
109. [109] Cernea, S., Dobreanu, M., Diabetes and beta cell function: from mechanisms to evaluation and clinical implications. Biochem. Med. 23 (2013), 266–280.
110. [110] DeFronzo, R.A., Eldor, R., Abdul-Ghani, M., Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes. Diabetes Care 36:Suppl. 2 (2013), S127–138.
111. [111] Gavrilova, O., Haluzik, M., Matsusue, K., Cutson, J.J., Johnson, L., Dietz, K.R., Nicol, C.J., Vinson, C., Gonzalez, F.J., Reitman, M.L., Liver peroxisome proliferator-activated receptor gamma contributes to hepatic steatosis, triglyceride clearance, and regulation of body fat mass. J. Biol. Chem. 278 (2003), 34268–34276.
112. [112] Nesto, R.W., Bell, D., Bonow, R.O., Fonseca, V., Grundy, S.M., Horton, E.S., Le Winter, M., Porte, D., Semenkovich, C.F., Smith, S., Young, L.H., Kahn, R., American Heart, A., American Diabetes, A., Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108 (2003), 2941–2948 (accessed 07.10.03).
113. [113] Cheng, A.Y., Fantus, I.G., Thiazolidinedione-induced congestive heart failure. Ann .Pharmacother. 38 (2004), 817–820.
114. [114] Levine, R., Sulfonylureas: background and development of the field. Diabetes Care 7:Suppl. 1 (1984), 3–7.
115. [115] Kreisberg, R.A., The second-generation sulfonylureas: change or progress?. Ann. Intern. Med. 102 (1985), 125–126.
116. [116] Aquilante, C.L., Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Rev. Cardiovasc. Ther. 8 (2010), 359–372.
117. [117] Groop, L.C., Sulfonylureas in NIDDM. Diabetes Care 15 (1992), 737–754.
118. [118] Nichols, C.G., KATP channels as molecular sensors of cellular metabolism. Nature 440 (2006), 470–476.
119. [119] Li, A., Knutsen, R.H., Zhang, H., Osei-Owusu, P., Moreno-Dominguez, A., Harter, T.M., Uchida, K., Remedi, M.S., Dietrich, H.H., Bernal-Mizrachi, C., Blumer, K.J., Mecham, R.P., Koster, J.C., Nichols, C.G., Hypotension due to Kir6.1 gain-of-function in vascular smooth muscle. J. Am. Heart Assoc., 2, 2013, e000365.
120. [120] Martin, G.M., Chen, P.C., Devaraneni, P., Shyng, S.L., Pharmacological rescue of trafficking-impaired ATP-sensitive potassium channels. Front. Physiol., 4, 2013, 386.
121. [121] Ashcroft, F.M., Gribble, F.M., Tissue-specific effects of sulfonylureas: lessons from studies of cloned K(ATP) channels. J. Diabetes Complications 14 (2000), 192–196.
122. [122] Tarasov, A., Dusonchet, J., Ashcroft, F., Metabolic regulation of the pancreatic beta-cell ATP-sensitive K+ channel: a pas de deux. Diabetes 53:Suppl. 3 (2004), S113–122.
123. [123] Ashcroft, F.M., The walter B. cannon physiology in perspective lecture,. ATP-sensitive K+ channels and disease: from molecule to malady. Am. J. Physiol. Endocrinol. Metab., 89, 2007, 2007.
124. [124] Seino, S., Zhang, C.L., Shibasaki, T., Sulfonylurea action re-revisited. J. Diabetes Invest. 1 (2010), 37–39.
125. [125] Henquin, J.C., Regulation of insulin secretion: a matter of phase control and amplitude modulation. Diabetologia 52 (2009), 739–751.
126. [126] Rorsman, P., Renstrom, E., Insulin granule dynamics in pancreatic beta cells. Diabetologia 46 (2003), 1029–1045.
127. [127] Straub, S.G., Shanmugam, G., Sharp, G.W., Stimulation of insulin release by glucose is associated with an increase in the number of docked granules in the beta-cells of rat pancreatic islets. Diabetes 53 (2004), 3179–3183.
128. [128] Gloyn, A.L., Pearson, E.R., Antcliff, J.F., Proks, P., Bruining, G.J., Slingerland, A.S., Howard, N., Srinivasan, S., Silva, J.M., Molnes, J., Edghill, E.L., Frayling, T.M., Temple, I.K., Mackay, D., Shield, J.P., Sumnik, Z., van Rhijn, A., Wales, J.K., Clark, P., Gorman, S., Aisenberg, J., Ellard, S., Njolstad, P.R., Ashcroft, F.M., Hattersley, A.T., Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N. Engl. J. Med. 350 (2004), 1838–1849.
129. [129] Cnop, M., Welsh, N., Jonas, J.C., Jorns, A., Lenzen, S., Eizirik, D.L., Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 54:Suppl. 2 (2005), S97–107.
130. [130] Ashcroftand, F., Rorsman, P., Type 2 diabetes mellitus: not quite exciting enough?. Hum. Mol. Genet. 13 (2004), R21–R31 (Spec No 1).
131. [131] Thorens, B., Wu, Y.J., Leahy, J.L., Weir, G.C., The loss of GLUT2 expression by glucose-unresponsive beta cells of db/db mice is reversible and is induced by the diabetic environment. J. Clin. Invest. 90 (1992), 77–85.
132. [132] Sturgess, N.C., Ashford, M.L., Cook, D.L., Hales, C.N., The sulphonylurea receptor may be an ATP-sensitive potassium channel. Lancet 2 (1985), 474–475.
133. [133] Gribble, F.M., Tucker, S.J., Ashcroft, F.M., The interaction of nucleotides with the tolbutamide block of cloned ATP-sensitive K+ channel currents expressed in Xenopus oocytes: a reinterpretation. J. Physiol. 504:Pt 1 (1997), 35–45.
134. [134] Proks, P., Reimann, F., Green, N., Gribble, F., Ashcroft, F., Sulfonylurea stimulation of insulin secretion. Diabetes 51:Suppl. 3 (2002), S368–376.
135. [135] Parnell, E., Palmer, T.M., Yarwood, S.J., The future of EPAC-targeted therapies: agonism versus antagonism. Trends Pharmacol. Sci. 36 (2015), 203–214.
136. [136] Zhang, C.L., Katoh, M., Shibasaki, T., Minami, K., Sunaga, Y., Takahashi, H., Yokoi, N., Iwasaki, M., Miki, T., Seino, S., The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs. Science 325 (2009), 607–610.
137. [137] Soundarapandian, M.M., Zhong, X., Peng, L., Wu, D., Lu, Y., Role of K(ATP) channels in protection against neuronal excitatory insults. J. Neurochem. 103 (2007), 1721–1729.
138. [138] Sun, H.S., Feng, Z.P., Neuroprotective role of ATP-sensitive potassium channels in cerebral ischemia. Acta Pharmacol. Sin. 34 (2013), 24–32.
139. [139] Miki, T., Liss, B., Minami, K., Shiuchi, T., Saraya, A., Kashima, Y., Horiuchi, M., Ashcroft, F., Minokoshi, Y., Roeper, J., Seino, S., ATP-sensitive K+ channels in the hypothalamus are essential for the maintenance of glucose homeostasis. Nat. Neurosci. 4 (2001), 507–512.
140. [140] Quayle, J.M., Nelson, M.T., Standen, N.B., ATP-sensitive and inwardly rectifying potassium channels in smooth muscle. Physiol. Rev. 77 (1997), 1165–1232.
141. [141] Minami, K., Miki, T., Kadowaki, T., Seino, S., Roles of ATP-sensitive K+ channels as metabolic sensors: studies of Kir6. x null mice. Diabetes. 53:Suppl. 3 (2004), S176–180.
142. [142] Wascherand, T.C., Boes, U., Ischemia in type 2 diabetes: tissue selectivity of sulfonylureas and clinical implications. Metabolism 52 (2003), 3–5.
143. [143] Del Prato, S., Vigili de Kreutzenberg, S., Riccio, A., Tiengo, A., Hepatic sensitivity to insulin: effects of sulfonylurea drugs. Am. J. Med. 90 (1991), 29S–36S.
144. [144] Kaku, K., Inoue, Y., Kaneko, T., Extrapancreatic effects of sulfonylurea drugs. Diabetes Res. Clin. Pract. 28:Suppl (1995), S105–S108.
145. [145] Imamur, H., Morimoto, I., Tanaka, Y., Hashimoto, O., Kanda, K., Yamashita, S., Eto, S., Regulation of glucose transporter 1 expression by gliclazide in rat L6 myoblasts. Diabetes Nutr. Metab. 14 (2001), 308–314.
146. [146] Haupt, A., Kausch, C., Dahl, D., Bachmann, O., Stumvoll, M., Haring, H.U., Matthaei, S., Effect of glimepiride on insulin-stimulated glycogen synthesis in cultured human skeletal muscle cells: a comparison to glibenclamide. Diabetes Care 25 (2002), 2129–2132.
147. [147] Tsiani, E., Ramlal, T., Leiter, L.A., Klip, A., Fantus, I.G., Stimulation of glucose uptake and increased plasma membrane content of glucose transporters in L6 skeletal muscle cells by the sulfonylureas gliclazide and glyburide. Endocrinology 136 (1995), 2505–2512.
148. [148] Krentz, A.J., Bailey, C.J., Oral antidiabetic agents: current role in type 2 diabetes mellitus. Drugs 65 (2005), 385–411.
149. [149] Guardado-Mendoza, R., Prioletta, A., Jimenez-Ceja, L.M., Sosale, A., Folli, F., The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus. Arch. Med. Sci.: AMS 9 (2013), 936–943.
150. [150] Maedler, K., Carr, R.D., Bosco, D., Zuellig, R.A., Berney, T., Donath, M.Y., Sulfonylurea induced beta-cell apoptosis in cultured human islets. J. Clin. Endocrinol. Metab. 90 (2005), 501–506.
151. [151] Thisted, H., Johnsen, S.P., Rungby, J., Sulfonylureas and the risk of myocardial infarction. Metabolism 55 (2006), S16–S19.
152. [152] Harrower, A.D., Comparative tolerability of sulphonylureas in diabetes mellitus. Drug Saf. 22 (2000), 313–320.
153. [153] Kimoto, K., Suzuki, K., Kizaki, T., Hitomi, Y., Ishida, H., Katsuta, H., Itoh, E., Ookawara, T., Suzuki, K., Honke, K., Ohno, H., Gliclazide protects pancreatic beta-cells from damage by hydrogen peroxide. Biochem. Biophys. Res. Commun. 303 (2003), 112–119.
154. [154] Keilson, L., Mather, S., Walter, Y.H., Subramanian, S., McLeod, J.F., Synergistic effects of nateglinide and meal administration on insulin secretion in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 85 (2000), 1081–1086.
155. [155] Blickle, J.F., Meglitinide analogues: a review of clinical data focused on recent trials, Diabetes &. Metabolism 32 (2006), 113–120.
156. [156] Talib, G.V., Tapadia, S.H., Inamdar, A., A study on insulin and its analogues for control of abnormal glycosylated haemoglobin in controlled or near-controlled type II diabetes mellitus patients on oral hypoglycaemic agents. JIACM, 15, 2014.
157. [157] Hansen, A.M., Christensen, I.T., Hansen, J.B., Carr, R.D., Ashcroft, F.M., Wahl, P., Differential interactions of nateglinide and repaglinide on the human beta-cell sulphonylurea receptor 1. Diabetes 51 (2002), 2789–2795.
158. [158] Hansen, A.M., Hansen, J.B., Carr, R.D., Ashcroft, F.M., Wahl, P., Kir6.2-dependent high-affinity repaglinide binding to beta-cell K(ATP) channels. Br. J. Pharmacol. 144 (2005), 551–557.
159. [159] Evans, J.L., Balkan, B., Rushakoff, R.J., DeGroot, L.J., Beck-Peccoz, P., Chrousos, G., Dungan, K., Grossman, A., Hershman, J.M., Koch, C., McLachlan, R., New, M., Rebar, R., Singer, F., Vinik, A., Weickert, M.O., (eds.) Oral and Injectable (Non-insulin) Pharmacological Agents for Type 2 Diabetes, 2000, Endotext, South Dartmouth (MA).
160. [160] Shigeto, M., Katsura, M., Matsuda, M., Ohkuma, S., Kaku, K., Nateglinide and mitiglinide, but not sulfonylureas, induce insulin secretion through a mechanism mediated by calcium release from endoplasmic reticulum. J. Pharmacol. Exp. Ther. 322 (2007), 1–7.
161. [161] Johnson, J.D., Kuang, S., Misler, S., Polonsky, K.S., Ryanodine receptors in human pancreatic beta cells: localization and effects on insulin secretion. FASEB J. 18 (2004), 878–880.
162. [162] Ristic, S., Collober-Maugeais, C., Pecher, E., Cressier, F., Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabetic Med.: J. Br. Diabetic Assoc. 23 (2006), 757–762.
163. [163] Ohkura, T., Inoue, K., Fujioka, Y., Nakanishi, R., Shiochi, H., Sumi, K., Yamamoto, N., Matsuzawa, K., Izawa, S., Ohkura, H., Kato, M., Yamamoto, K., Taniguchi, S., The proinsulin/insulin (PI/I) ratio is reduced by postprandial targeting therapy in type 2 diabetes mellitus: a small-scale clinical study. BMC research notes., 6, 2013, 453.
164. [164] Fowler, M.J., Diabetes treatment, part 2: oral agents for glycemic management. Clin.Diabetes 25 (2007), 131–134.
165. [165] Sanyal, D., Diabetes is predominantly an intestinal disease. Indian J. Endocrinol. Metab. 17 (2013), S64–S67.
166. [166] Ross, S.A., Ekoe, J.M., Incretin agents in type 2 diabetes. Canadian Family Physician Medecin de Famille Canadien. 56 (2010), 639–648.
167. [167] Holst, J.J., The physiology of glucagon-like peptide 1. Physiol. Rev. 87 (2007), 1409–1439.
168. [168] Nauck, M.A., Vardarli, I., Deacon, C.F., Holst, J.J., Meier, J.J., Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?. Diabetologia 54 (2011), 10–18.
169. [169] Holst, J.J., Knop, F.K., Vilsboll, T., Krarup, T., Madsbad, S., Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 34:Suppl. 2 (2011), S251–257.
170. [170] Nauck, M.A., Heimesaat, M.M., Orskov, C., Holst, J.J., Ebert, R., Creutzfeldt, W., Preserved incretin activity of glucagon-like peptide 1 [7–36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J. Clin. Invest. 91 (1993), 301–307.
171. [171] Mentis, N., Vardarli, I., Kothe, L.D., Holst, J.J., Deacon, C.F., Theodorakis, M., Meier, J.J., Nauck, M.A., GIP does not potentiate the antidiabetic effects of GLP-1 in hyperglycemic patients with type 2 diabetes. Diabetes 60 (2011), 1270–1276.
172. [172] Drucker, D.J., Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26 (2003), 2929–2940.
173. [173] Nisal, K., Kela, R., Khunti, K., Davies, M.J., Comparison of efficacy between incretin-based therapies for type 2 diabetes mellitus. BMC Med., 10, 2012, 152.
174. [174] Egan, J.M., Meneilly, G.S., Elahi, D., Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes. Am. J. Physiol. Endocrinol. Metab. 284 (2003), E1072–1079.
175. [175] Neumiller, J.J., Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. J. Am. Pharm. Assoc.: JAPhA 49:Suppl. 1 (2009), S16–S29.
176. [176] Kushwaha, R.N., Haq, W., Katti, S.B., Discovery of 17 gliptins in 17-years of research for the treatment of type 2 diabetes a synthetic overview. Chem. Biol. Interface, 4, 2014.
177. [177] Drucker, D.J., Sherman, S.I., Gorelick, F.S., Bergenstal, R.M., Sherwin, R.S., Buse, J.B., Incretin-based therapies for the treatment of type 2 diabetes: evaluation of the risks and benefits. Diabetes Care 33 (2010), 428–433.
178. [178] Leech, C.A., Dzhura, I., Chepurny, O.G., Schwede, F., Genieser, H.G., Holz, G.G., Facilitation of ss-cell K(ATP) channel sulfonylurea sensitivity by a cAMP analog selective for the cAMP-regulated guanine nucleotide exchange factor Epac. Islets 2 (2010), 72–81.
179. [179] Kashima, Y., Miki, T., Shibasaki, T., Ozaki, N., Miyazaki, M., Yano, H., Seino, S., Critical role of cAMP-GEFII–Rim2 complex in incretin-potentiated insulin secretion. J. Biol. Chem. 276 (2001), 46046–46053.
180. [180] Yosida, M., Dezaki, K., Uchida, K., Kodera, S., Lam, N.V., Ito, K., Rita, R.S., Yamada, H., Shimomura, K., Ishikawa, S.E., Sugawara, H., Kawakami, M., Tominaga, M., Yada, T., Kakei, M., Involvement of cAMP/EPAC/TRPM2 activation in glucose- and incretin-induced insulin secretion. Diabetes 63 (2014), 3394–3403.
181. [181] Holz, G.G., Epac A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell. Diabetes 53 (2004), 5–13.
182. [182] Fujita, Y., Haneda, M., Molecular mechanism of insulin secretion facilitated by incretin. Nihon Rinsho Jpn. J. Clin. Med. 69 (2011), 808–812.
183. [183] Uchida, K., Dezaki, K., Damdindorj, B., Inada, H., Shiuchi, T., Mori, Y., Yada, T., Minokoshi, Y., Tominaga, M., Lack of TRPM2 impaired insulin secretion and glucose metabolisms in mice. Diabetes 60 (2011), 119–126.
184. [184] Holz, G.G., Kang, G., Harbeck, M., Roe, M.W., Chepurny, O.G., Cell physiology of cAMP sensor Epac. J. Physiol. 577 (2006), 5–15.
185. [185] Schmidt, M., Evellin, S., Weernink, P.A., von Dorp, F., Rehmann, H., Lomasney, J.W., Jakobs, K.H., A new phospholipase-C-calcium signalling pathway mediated by cyclic AMP and a Rap GTPase. Nat. Cell Biol. 3 (2001), 1020–1024.
186. [186] Baukrowitz, T., Schulte, U., Oliver, D., Herlitze, S., Krauter, T., Tucker, S.J., Ruppersberg, J.P., Fakler, B., PIP2 and PIP as determinants for ATP inhibition of KATP channels. Science 282 (1998), 1141–1144.
187. [187] Shyng, S.L., Nichols, C.G., Membrane phospholipid control of nucleotide sensitivity of KATP channels. Science 282 (1998), 1138–1141.
188. [188] Tsuboi, T., da Silva Xavier, G., Holz, G.G., Jouaville, L.S., Thomas, A.P., Rutter, G.A., Glucagon-like peptide-1 mobilizes intracellular Ca2+ and stimulates mitochondrial ATP synthesis in pancreatic MIN6 beta-cells. Biochem. J. 369 (2003), 287–299.
189. [189] Suzuki, Y., Zhang, H., Saito, N., Kojima, I., Urano, T., Mogami, H., Glucagon-like peptide 1 activates protein kinase C through Ca2+-dependent activation of phospholipase C in insulin-secreting cells. J. Biol. Chem. 281 (2006), 28499–28507.
190. [190] Turk, J., Gross, R.W., Ramanadham, S., Amplification of insulin secretion by lipid messengers. Diabetes 42 (1993), 367–374.
191. [191] Fujimoto, K., Shibasaki, T., Yokoi, N., Kashima, Y., Matsumoto, M., Sasaki, T., Tajima, N., Iwanaga, T., Seino, S., Piccolo a Ca2+ sensor in pancreatic beta-cells. Involvement of cAMP-GEFII. Rim2. Piccolo complex in cAMP-dependent exocytosis. J. Biol. Chem. 277 (2002), 50497–50502.
192. [192] Yaekura, K., Julyan, R., Wicksteed, B.L., Hays, L.B., Alarcon, C., Sommers, S., Poitout, V., Baskin, D.G., Wang, Y., Philipson, L.H., Rhodes, C.J., Insulin secretory deficiency and glucose intolerance in Rab3A null mice. J. Biol. Chem. 278 (2003), 9715–9972.
193. [193] Daniel, S., Noda, M., Straub, S.G., Sharp, G.W., Identification of the docked granule pool responsible for the first phase of glucose-stimulated insulin secretion. Diabetes 48 (1999), 1686–1690.
194. [194] Park, J.H., Kim, S.J., Park, S.H., Son, D.G., Bae, J.H., Kim, H.K., Han, J., Song, D.K., Glucagon-like peptide-1 enhances glucokinase activity in pancreatic beta-cells through the association of Epac2 with Rim2 and Rab3A. Endocrinology 153 (2012), 574–582.
195. [195] Light, P.E., Manning Fox, J.E., Riedel, M.J., Wheeler, M.B., Glucagon-like peptide-1 inhibits pancreatic ATP-sensitive potassium channels via a protein kinase A- and ADP-dependent mechanism. Mol. Endocrinol. 16 (2002), 2135–2144.
196. [196] Holz, G.G.t., Kuhtreiber, W.M., Habener, J.F., Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7–37). Nature 361 (1993), 362–365.
197. [197] Rhee, S.G., Regulation of phosphoinositide-specific phospholipase C. Annu. Rev. Biochem. 70 (2001), 281–312.
198. [198] Tong, Q., Zhang, W., Conrad, K., Mostoller, K., Cheung, J.Y., Peterson, B.Z., Miller, B.A., Regulation of the transient receptor potential channel TRPM2 by the Ca2+ sensor calmodulin. J. Biol. Chem. 281 (2006), 9076–9908.
199. [199] Doyle, M.E., Egan, J.M., Mechanisms of action of glucagon-like peptide 1 in the pancreas. Pharmacol. Ther. 113 (2007), 546–593.
200. [200] Hussain, M.A., Porras, D.L., Rowe, M.H., West, J.R., Song, W.J., Schreiber, W.E., Wondisford, F.E., Increased pancreatic beta-cell proliferation mediated by CREB binding protein gene activation. Mol. Cell. Biol. 26 (2006), 7747–7759.
201. [201] Stoffers, D.A., Kieffer, T.J., Hussain, M.A., Drucker, D.J., Bonner-Weir, S., Habener, J.F., Egan, J.M., Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 49 (2000), 741–748.
202. [202] Ahren, B., GLP-1 for type 2 diabetes. Exp. Cell Res. 317 (2011), 1239–1245.
203. [203] Mu, J., Woods, J., Zhou, Y.P., Roy, R.S., Li, Z., Zycband, E., Feng, Y., Zhu, L., Li, C., Howard, A.D., Moller, D.E., Thornberry, N.A., Zhang, B.B., Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic beta-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006), 1695–1704.
204. [204] Pospisilik, J.A., Martin, J., Doty, T., Ehses, J.A., Pamir, N., Lynn, F.C., Piteau, S., Demuth, H.U., McIntosh, C.H., Pederson, R.A., Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 (2003), 741–750.
205. [205] Hamamoto, S., Kanda, Y., Shimoda, M., Tatsumi, F., Kohara, K., Tawaramoto, K., Hashiramoto, M., Kaku, K., Vildagliptin preserves the mass and function of pancreatic beta cells via the developmental regulation and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes. Diabetes Obes. Metab. 15 (2013), 153–163.
206. [206] Barnett, A., DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int. J. Clin. Pract. 60 (2006), 1454–1470.
207. [207] Fadini, G.P., Boscaro, E., Albiero, M., Menegazzo, L., Frison, V., de Kreutzenberg, S., Agostini, C., Tiengo, A., Avogaro, A., The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 33 (2010), 1607–1609.
208. [208] Liu, Z., Stanojevic, V., Avadhani, S., Yano, T., Habener, J.F., Stromal cell-derived factor-1 (SDF-1)/chemokine (C-X-C motif) receptor 4 (CXCR4) axis activation induces intra-islet glucagon-like peptide-1 (GLP-1) production and enhances beta cell survival. Diabetologia 54 (2011), 2067–2076.
209. [209] Waget, A., Cabou, C., Masseboeuf, M., Cattan, P., Armanet, M., Karaca, M., Castel, J., Garret, C., Payros, G., Maida, A., Sulpice, T., Holst, J.J., Drucker, D.J., Magnan, C., Burcelin, R., Physiological and pharmacological mechanisms through which the DPP-4 inhibitor sitagliptin regulates glycemia in mice. Endocrinology 152 (2011), 3018–3029.
210. [210] Fujiwara, K., Gotoh, K., Chiba, S., Masaki, T., Katsuragi, I., Kakuma, T., Yoshimatsu, H., Intraportal administration of DPP-IV inhibitor regulates insulin secretion and food intake mediated by the hepatic vagal afferent nerve in rats. J. Neurochem. 121 (2012), 66–76.
211. [211] Muscelli, E., Casolaro, A., Gastaldelli, A., Mari, A., Seghieri, G., Astiarraga, B., Chen, Y., Alba, M., Holst, J., Ferrannini, E., Mechanisms for the antihyperglycemic effect of sitagliptin in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 97 (2012), 2818–2826.
212. [212] Shah, P., Ardestani, A., Dharmadhikari, G., Laue, S., Schumann, D.M., Kerr-Conte, J., Pattou, F., Klein, T., Maedler, K., The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization. J. Clin. Endocrinol. Metab. 98 (2013), E1163–1172.
213. [213] Omar, B., Ahren, B., Pleiotropic mechanisms for the glucose-lowering action of DPP-4 inhibitors. Diabetes 63 (2014), 2196–2202.
214. [214] Lee, Y.S., Jun, H.S., Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells. Metabolism 63 (2014), 9–19.
215. [215] Pyke, C., Heller, R.S., Kirk, R.K., Orskov, C., Reedtz-Runge, S., Kaastrup, P., Hvelplund, A., Bardram, L., Calatayud, D., Knudsen, L.B., GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody. Endocrinology 155 (2014), 1280–1290.
216. [216] Simo, R., Guerci, B., Schernthaner, G., Gallwitz, B., Rosas-Guzman, J., Dotta, F., Festa, A., Zhou, M., Kiljanski, J., Long-term changes in cardiovascular risk markers during administration of exenatide twice daily or glimepiride: results from the European exenatide study. Cardiovasc. Diabetol., 14, 2015, 116.
217. [217] Filippatos, T.D., Panagiotopoulou, T.V., Elisaf, M.S., Adverse effects of GLP-1 receptor agonists. Rev. Diabetic Stud.: RDS 11 (2014), 202–230.
218. [218] Liu, W., Li, Y., Jalewa, J., Saunders-Wood, T., Li, L., Holscher, C., Neuroprotective effects of an oxyntomodulin analogue in the MPTP mouse model of Parkinson's disease. Eur. J. Pharmacol. 765 (2015), 284–290.
219. [219] Seufert, J., Gallwitz, B., The extra-pancreatic effects of GLP-1 receptor agonists: a focus on the cardiovascular, gastrointestinal and central nervous systems. Diabetes Obes. Metab. 16 (2014), 673–688.
220. [220] Xu, F., Li, Z., Zheng, X., Liu, H., Liang, H., Xu, H., Chen, Z., Zeng, K., Weng, J., SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes 63 (2014), 3637–3646.
221. [221] Thingholm, T.E., Bak, S., Beck-Nielsen, H., Jensen, O.N., Gaster, M., Characterization of human myotubes from type 2 diabetic and nondiabetic subjects using complementary quantitative mass spectrometric methods. Mol. Cell. Proteom.: MCP., 10, 2011, 006650 (M110).
222. [222] Wu, H., Sui, C., Xia, F., Zhai, H., Zhang, H., Xu, H., Weng, P., Lu, Y., Effects of exenatide therapy on insulin resistance in the skeletal muscles of high-fat diet and low-dose streptozotocin-induced diabetic rats. Endocr. Res., 2015, 1–7.
223. [223] Idris, I., Patiag, D., Gray, S., Donnelly, R., Exendin-4 increases insulin sensitivity via a PI-3-kinase-dependent mechanism: contrasting effects of GLP-1. Biochem. Pharmacol. 63 (2002), 993–996.
224. [224] a. Buse, K.D.J., Glucagon-like Peptide 1–based therapies for type 2 diabetes a focus on exenatide. Clin. Diabetes, 23, 2005.
225. [225] Sjoberg, K.A., Rattigan, S., Jeppesen, J.F., Lundsgaard, A.M., Holst, J.J., Kiens, B., Differential effects of glucagon-like peptide-1 on microvascular recruitment and glucose metabolism in short- and long-term insulin resistance. J. Physiol. 593 (2015), 2185–2198.
226. [226] Abdulla, H., Phillips, B., Smith, K., Wilkinson, D., Atherton, P.J., Idris, I., Physiological mechanisms of action of incretin and insulin in regulating skeletal muscle metabolism. Curr. Diabetes Rev. 10 (2014), 327–335.
227. [227] Sjoberg, K.A., Holst, J.J., Rattigan, S., Richter, E.A., Kiens, B., GLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle. Am. J. Physiol. Endocrinol. Metab. 306 (2014), E355–362.
228. [228] Subaran, S.C., Sauder, M.A., Chai, W., Jahn, L.A., Fowler, D.E., Aylor, K.W., Basu, A., Liu, Z., GLP-1 at physiological concentrations recruits skeletal and cardiac muscle microvasculature in healthy humans. Clin. Sci. 127 (2014), 163–170.
229. [229] Green, C.J., Henriksen, T.I., Pedersen, B.K., Solomon, T.P., Glucagon like peptide-1-induced glucose metabolism in differentiated human muscle satellite cells is attenuated by hyperglycemia. PLoS One, 7, 2012, e44284.
230. [230] Acitores, A., Gonzalez, N., Sancho, V., Valverde, I., Villanueva-Penacarrillo, M.L., Cell signalling of glucagon-like peptide-1 action in rat skeletal muscle. J. Endocrinol. 180 (2004), 389–398.
231. [231] Honors, M.A., Kinzig, K.P., Chronic exendin-4 treatment prevents the development of cancer cachexia symptoms in male rats bearing the Yoshida sarcoma. Hormones Cancer 5 (2014), 33–41.
232. [232] Wang, L., Guo, F., Wei, S., Zhao, R., Divergent effects of GLP-1 analogs exendin-4 and exendin-9 on the expression of myosin heavy chain isoforms in C2C12 myotubes. Peptides 32 (2011), 1313–1319.
233. [233] Ji, W., Chen, X., Lv, J., Wang, M., Ren, S., Yuan, B., Wang, B., Chen, L., Liraglutide Exerts Antidiabetic Effect via PTP1 B and PI3 K/Akt2 Signaling Pathway in Skeletal Muscle of KKAy Mice. Int. J. Endocrinol., 312452, 2014, 2014.
234. [234] Li, Z., Ni, C.L., Yao, Z., Chen, L.M., Niu, W.Y., Liraglutide enhances glucose transporter 4 translocation via regulation of AMP-activated protein kinase signaling pathways in mouse skeletal muscle cells. Metabolism 63 (2014), 1022–1030.
235. [235] Chen, L.N., Lyu, J., Yang, X.F., Ji, W.J., Yuan, B.X., Chen, M.X., Ma, X., Wang, B., Liraglutide ameliorates glycometabolism and insulin resistance through the upregulation of GLUT4 in diabetic KKAy mice. Int. J. Mol. Med. 32 (2013), 892–900.
236. [236] Giannocco, G., Oliveira, K.C., Crajoinas, R.O., Venturini, G., Salles, T.A., Fonseca-Alaniz, M.H., Maciel, R.M., Girardi, A.C., Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats. Eur. J. Pharmacol. 698 (2013), 74–86.
237. [237] Bouzakri, K., Plomgaard, P., Berney, T., Donath, M.Y., Pedersen, B.K., Halban, P.A., Bimodal effect on pancreatic beta-cells of secretory products from normal or insulin-resistant human skeletal muscle. Diabetes 60 (2011), 1111–1121.
238. [238] Tella, S.H., Rendell, M.S., Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability: a balance. Ther. Adv. Endocrinol. Metab. 6 (2015), 109–134.
239. [239] van Bloemendaal, L., Veltman, D.J., ten Kulve, J.S., Drent, M.L., Barkhof, F., Diamant, M., Emotional eating is associated with increased brain responses to food-cues and reduced sensitivity to GLP-1 receptor activation. Obesity 23 (2015), 2075–2082.
240. [240] Shalev, A., Holst, J.J., Keller, U., Effects of glucagon-like peptide 1 (7–36 amide) on whole-body protein metabolism in healthy man. Eur. J. Clin. Invest. 27 (1997), 10–16.
241. [241] Vendrell, J., El Bekay, R., Peral, B., Garcia-Fuentes, E., Megia, A., Macias-Gonzalez, M., Fernandez Real, J., Jimenez-Gomez, Y., Escote, X., Pachon, G., Simo, R., Selva, D.M., Malagon, M.M., Tinahones, F.J., Study of the potential association of adipose tissue GLP-1 receptor with obesity and insulin resistance. Endocrinology 152 (2011), 4072–4079.
242. [242] Sengenes, C., Berlan, M., De Glisezinski, I., Lafontan, M., Galitzky, J., Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 14 (2000), 1345–1351.
243. [243] Li, C.J., Yu, Q., Yu, P., Yu, T.L., Zhang, Q.M., Lu, S., Yu Changes, D.M., in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc. Diabetol., 13, 2014, 36.
244. [244] Beiroa, D., Imbernon, M., Gallego, R., Senra, A., Herranz, D., Villarroya, F., Serrano, M., Ferno, J., Salvador, J., Escalada, J., Dieguez, C., Lopez, M., Fruhbeck, G., Nogueiras, R., GLP-1 agonism stimulates brown adipose tissue thermogenesis and browning through hypothalamic AMPK. Diabetes 63 (2014), 3346–3358.
245. [245] Prasad-Reddyand, L., Isaacs, D., A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond. Drugs Context, 4(212283), 2015.
246. [246] Gurung, T., Shyangdan, D.S., O'Hare, J.P., Waugh, N., A novel, long-acting glucagon-like peptide receptor-agonist: dulaglutide. Diabetes Metab. Syndr. Obes.: Targets Ther. 8 (2015), 363–386.
247. [247] Mosley, J.F., 2nd, Smith, L., Everton, E., Fellner, C., Sodium-Glucose Linked Transporter 2 (SGLT2) Inhibitors in the Management Of Type-2 Diabetes: A Drug Class Overview. P & T a Peer-Rev. J. Formul. Manage. 40 (2015), 451–462.
248. [248] Haas, B., Eckstein, N., Pfeifer, V., Mayer, P., Hass, M.D., Efficacy, safety and regulatory status of SGLT2 inhibitors: focus on canagliflozin. Nutr. Diabetes, 4, 2014, e143.
249. [249] Rasania, S., Singhal, M., Gaur, Amit, Manchireddy Vishnu, V.R., Vijaya, S., Raju, R., Upadhyay, Y., Overview on sodium glucose transport inhibitors as a therapeutic tool against diabetes mellitus. Global J. Pharmacol., 6, 2012.
250. [250] Wright, E.M., Loo, D.D., Hirayama, B.A., Biology of human sodium glucose transporters. Physiol. Rev. 91 (2011), 733–794.
251. [251] Zanoli, L., Granata, A., Lentini, P., Rastelli, S., Fatuzzo, P., Rapisarda, F., Castellino, P., Sodium-glucose linked transporter-2 inhibitors in chronic kidney disease. Sci. World J., 2015, 2015, 317507.
252. [252] Liu, J.J., Lee, T., DeFronzo, R.A., Why Do SGLT2 inhibitors inhibit only 30–50% of renal glucose reabsorption in humans?. Diabetes 61 (2012), 2199–2204.
253. [253] Mogensen, C.E., Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand. J. Clin. Lab. Invest. 28 (1971), 101–109.
254. [254] Rahmoune, H., Thompson, P.W., Ward, J.M., Smith, C.D., Hong, G., Brown, J., Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 54 (2005), 3427–3434.
255. [255] Dieter, M., Palmada, M., Rajamanickam, J., Aydin, A., Busjahn, A., Boehmer, C., Luft, F.C., Lang, F., Regulation of glucose transporter SGLT1 by ubiquitin ligase Nedd4-2 and kinases SGK1, SGK3, and PKB. Obes. Res. 12 (2004), 862–870.
256. [256] Linden, K.C., DeHaan, C.L., Zhang, Y., Glowacka, S., Cox, A.J., Kelly, D.J., Rogers, S., Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am. J. Physiol. Renal. Physiol. 290 (2006), F205–213.
257. [257] Tabatabai, N.M., Sharma, M., Blumenthal, S.S., Petering, D.H., Enhanced expressions of sodium-glucose cotransporters in the kidneys of diabetic Zucker rats. Diabetes Res. Clin. Pract. 83 (2009), e27–30.
258. [258] Vallon, V., The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus. Annu. Rev. Med. 66 (2015), 255–270.
259. [259] Freitas, H.S., Anhe, G.F., Melo, K.F., Okamoto, M.M., Oliveira-Souza, M., Bordin, S., Machado, U.F., Na(+)−glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 149 (2008), 717–724.
260. [260] Souza, M.S., Machado, U.F., Okamoto, M., Bertoluci, M.C., Ponpermeyer, C., Leguisamo, N., Azambuja, F., Irigoyen, M.C., Schaan, B.D., Reduced cortical renal GLUT1 expression induced by angiotensin-converting enzyme inhibition in diabetic spontaneously hypertensive rats. Brazilian Journal of Medical and Biological Research = Revista brasileira de pesquisas medicas e biologicas/Sociedade Brasileira de Biofisica [et al] 41 (2008), 960–968.
261. [261] Lang, F., Gorlach, A., Vallon, V., Targeting SGK1 in diabetes. Expert Opin. Ther. Targets 13 (2009), 1303–1311.
262. [262] Panchapakesan, U., Pegg, K., Gross, S., Komala, M.G., Mudaliar, H., Forbes, J., Pollock, C., Mather, A., Effects of SGL inhibition in human kidney proximal tubular cells?renoprotection in diabetic nephropathy?. PLoS One, 8, 2013, e54442.
263. [263] Wiecek, A., Chudek, J., Kokot, F., Role of angiotensin II in the progression of diabetic nephropathy-therapeutic implications. Nephrol. Dial. Transplant. 18:Suppl. 5 (2003), v16–v20.
264. [264] Bautista, R., Manning, R., Martinez, F., Avila-Casado Mdel, C., Soto, V., Medina, A., Escalante, B., Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension. Am. J. Physiol. Renal. Physiol. 286 (2004), F127–133.
265. [265] Goestemeyer, A.K., Marks, J., Srai, S.K., Debnam, E.S., Unwin, R.J., GLUT2 protein at the rat proximal tubule brush border membrane correlates with protein kinase C (PKC)-betal and plasma glucose concentration. Diabetologia 50 (2007), 2209–2217.
266. [266] Satriano, J., Vallon, V., Primary kidney growth and its consequences at the onset of diabetes mellitus. Amino Acids 31 (2006), 1–9.
267. [267] Meier, M., Park, J.K., Overheu, D., Kirsch, T., Lindschau, C., Gueler, F., Leitges, M., Menne, J., Haller, H., Deletion of protein kinase C-beta isoform in vivo reduces renal hypertrophy but not albuminuria in the streptozotocin-induced diabetic mouse model. Diabetes 56 (2007), 346–354.
268. [268] Noh, H., King, G.L., The role of protein kinase C activation in diabetic nephropathy. Kidney Int. Suppl., 2007, S49–S53.
269. [269] Han, H.J., Park, S.H., Lee, Y.J., Signaling cascade of ANG II-induced inhibition of alpha-MG uptake in renal proximal tubule cells. Am. J. Physiol. Renal. Physiol. 286 (2004), F634–642.
270. [270] Lee, Y.J., Lee, Y.J., Han, H.J., Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int. Suppl., 2007, S27–S35.
271. [271] Vallon, V., Blantz, R., Thomson, S., The salt paradox and its possible implications in managing hypertensive diabetic patients. Curr. Hypertens. Rep. 7 (2005), 141–147.
272. [272] Vallon, V., Thomson, S.C., Renal function in diabetic disease models: the tubular system in the pathophysiology of the diabetic kidney. Annu. Rev. Physiol. 74 (2012), 351–375.
273. [273] Toth-Manikowski, S., Atta, M.G., Diabetic kidney disease: pathophysiology and therapeutic targets. J. Diabetes Res., 2015(697010), 2015.
274. [274] Eid, A., Bodin, S., Ferrier, B., Delage, H., Boghossian, M., Martin, M., Baverel, G., Conjard, A., Intrinsic gluconeogenesis is enhanced in renal proximal tubules of Zucker diabetic fatty rats. J. Am. Soc. Nephrol.: JASN 17 (2006), 398–405.
275. [275] Mutel, E., Gautier-Stein, A., Abdul-Wahed, A., Amigo-Correig, M., Zitoun, C., Stefanutti, A., Houberdon, I., Tourette, J.A., Mithieux, G., Rajas, F., Control of blood glucose in the absence of hepatic glucose production during prolonged fasting in mice: induction of renal and intestinal gluconeogenesis by glucagon. Diabetes 60 (2011), 3121–3131.
276. [276] Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thevenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W.J., Sener, A., Deprez, B., Abderrahmani, A., Staels, B., Pattou, F., Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion. Nat. Med. 21 (2015), 512–517.
277. [277] Singh, V.P., Bali, A., Singh, N., Jaggi, A.S., Advanced glycation end products and diabetic complications. Korean J. Physiol. Pharmacol. 18 (2014), 1–14.
278. [278] Albertoni Borghese, M.F., Majowicz, M.P., Ortiz, M.C., Passalacqua Mdel, R., Sterin Speziale, N.B., Vidal, N.A., Expression and activity of SGLT2 in diabetes induced by streptozotocin: relationship with the lipid environment. Nephron Physiol. 112 (2009), 45–52.
279. [279] Washburn, W.N., Evolution of sodium glucose co-transporter 2 inhibitors as anti-diabetic agents. Expert Opin. Ther. Pat. 19 (2009), 1485–1499.
280. [280] Nair, S., Wilding, J.P., Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. J. Clin. Endocrinol. Metab. 95 (2010), 34–42.
281. [281] Bays, H., Sodium glucose co-transporter type 2 (SGLT2) inhibitors: targeting the kidney to improve glycemic control in diabetes mellitus. Diabetes Ther.: Res. Treat. Educ. Diabetes Relat. Disord. 4 (2013), 195–220.
282. [282] Chao, E.C., SGLT-2 inhibitors a new mechanism for glycemic control. Clin. Diabetes: Publ. Am. Diabetes Assoc. 32 (2014), 4–11.
283. [283] Imprialos, K.P., Sarafidis, P.A., Karagiannis, A.I., Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class?. J. Hypertens. 33 (2015), 2185–2197.
284. [284] Rossetti, L., Smith, D., Shulman, G.I., Papachristou, D., DeFronzo, R.A., Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J. Clin. Invest. 79 (1987), 1510–1515.
285. [285] Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T.V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M.A., DeFronzo, R.A., Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J. Clin. Invest. 124 (2014), 509–514.
286. [286] Tahara, A., Kurosaki, E., Yokono, M., Yamajuku, D., Kihara, R., Hayashizaki, Y., Takasu, T., Imamura, M., Li, Q., Tomiyama, H., Kobayashi, Y., Noda, A., Sasamata, M., Shibasaki, M., Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur. J. Pharmacol. 715 (2013), 246–255.
287. [287] Scheen, A.J., Esser, N., Paquot, N., Antidiabetic agents: potential anti-inflammatory activity beyond glucose control. Diabetes Metabol. 41 (2015), 183–194.
288. [288] Starke, A., Grundy, S., McGarry, J.D., Unger, R.H., Correction of hyperglycemia with phloridzin restores the glucagon response to glucose in insulin-deficient dogs: implications for human diabetes. Proc. Natl. Acad. Sci. U. S. A. 82 (1985), 1544–1546.
289. [289] Poudel, R.R., Renal glucose handling in diabetes and sodium glucose cotransporter 2 inhibition. Indian J. Endocrinol. Metab. 17 (2013), 588–593.
290. [290] Asano, T., Ogihara, T., Katagiri, H., Sakoda, H., Ono, H., Fujishiro, M., Anai, M., Kurihara, H., Uchijima, Y., Glucose transporter and Na+/glucose cotransporter as molecular targets of anti-diabetic drugs. Curr. Med. Chem. 11 (2004), 2717–2724.
291. [291] Isaji, M., Sodium-glucose cotransporter inhibitors for diabetes. Curr. Opin. Investig. Drugs 8 (2007), 285–292.
292. [292] Nomura, S., Sakamaki, S., Hongu, M., Kawanishi, E., Koga, Y., Sakamoto, T., Yamamoto, Y., Ueta, K., Kimata, H., Nakayama, K., Tsuda-Tsukimoto, M., Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. J. Med. Chem. 53 (2010), 6355–6360.
293. [293] EMA. http//www.ema.europa.eu/ema/.
294. [294] FDA. http//www.fda.gov/.
295. [295] Devineni, D., Morrow, L., Hompesch, M., Skee, D., Vandebosch, A., Murphy, J., Ways, K., Schwartz, S., Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes. Metab. 14 (2012), 539–545.
296. [296] Stenlof, K., Cefalu, W.T., Kim, K.A., Alba, M., Usiskin, K., Tong, C., Canovatchel, W., Meininger, G., Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes. Metab. 15 (2013), 372–382.
297. [297] Kasichayanula, S., Liu, X., Shyu, W.C., Zhang, W., Pfister, M., Griffen, S.C., Li, T., LaCreta, F.P., Boulton, D.W., Lack of pharmacokinetic interaction between dapagliflozin, a novel sodium-glucose transporter 2 inhibitor, and metformin, pioglitazone, glimepiride or sitagliptin in healthy subjects. Diabetes Obes. Metab. 13 (2011), 47–54.
298. [298] Hinnen, D., Glucuretic effects and renal safety of dapagliflozin in patients with type 2 diabetes. Ther. Adv. Endocrinol. Metab. 6 (2015), 92–102.
299. [299] Kaku, K., Inoue, S., Matsuoka, O., Kiyosue, A., Azuma, H., Hayashi, N., Tokudome, T., Langkilde, A.M., Parikh, S., Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes. Metab. 15 (2013), 432–440.
300. [300] Nauck, M.A., Del Prato, S., Meier, J.J., Duran-Garcia, S., Rohwedder, K., Elze, M., Parikh, S.J., Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care 34 (2011), 2015–2022.
301. [301] Lambers Heerspink, H.J., de Zeeuw, D., Wie, L., Leslie, B., List, J., Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes Obes. Metab. 15 (2013), 853–862.
302. [302] Ahmed, D., Sharma, M., Kumar, V., Yadav, P.S., An emerging protagonist: sodium glucose co-transporters (SGLTs) as a burgeoning target for the treatment of diabetes mellitus. J. Diabetes Metab., 5, 2014.
303. [303] Liu, X.Y., Zhang, N., Chen, R., Zhao, J.G., Yu, P., Efficacy and safety of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes: a meta-analysis of randomized controlled trials for 1 to 2years. J. Diabetes Complications 29 (2015), 1295–1303.
304. [304] Hedrington, M.S., Davis, S.N., The role of empagliflozin in the management of type 2 diabetes by patient profile. Ther. Clin. Risk Manage. 11 (2015), 739–749.
305. [305] Joshi, S.R., Standl, E., Tong, N., Shah, P., Kalra, S., Rathod, R., Therapeutic potential of alpha-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review. Expert Opin. Pharmacother. 16 (2015), 1959–1981.
306. [306] Lebovitz, H.E., Alpha-Glucosidase inhibitors. Endocrinol. Metab. Clin. North Am. 26 (1997), 539–551.
307. [307] Cheng, A.Y., Fantus, I.G., Oral antihyperglycemic therapy for type 2 diabetes mellitus. CMAJ: Canadian Medical Association Journal = Journal de l'Association Medicale Canadienne 172 (2005), 213–226.
308. [308] Quianzon, C.C., Cheikh, I.E., History of current non-insulin medications for diabetes mellitus. J. Commun. Hosp. Intern. Med. Perspect., 2, 2012.
309. [309] Dabhi, A.S., Bhatt, N.R., Shah, M.J., Voglibose: an alpha glucosidase inhibitor. J. Clin. Diagn. Res.: JCDR. 7 (2013), 3023–3027.
310. [310] van de Laar, F.A., Lucassen, P.L., Akkermans, R.P., van de Lisdonk, E.H., Rutten, G.E., van Weel, C., Alpha-glucosidase inhibitors for patients with type 2 diabetes: results from a Cochrane systematic review and meta-analysis. Diabetes Care 28 (2005), 154–163.
311. [311] Derosa, G., Maffioli, P., alpha-Glucosidase inhibitors and their use in clinical practice. Arch. Med. Sci. AMS 8 (2012), 899–906.
312. [312] Hillebrand, I., Boehme, K., Frank, G., Fink, H., Berchtold, P., The effects of the alpha-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: dose-time-response relationships in man. Research in Experimental Medicine Zeitschrift fur die gesamte Experimentelle Medizin Einschliesslich Experimenteller Chirurgie 175 (1979), 87–94.
313. [313] Ueno, T., Takeuchi, H., Kawasaki, K., Kubo, T., Changes in the gene expression profiles of the hypopharyngeal gland of worker honeybees in association with worker behavior and hormonal factors. PLoS One, 10, 2015, e0130206.
314. [314] N.F. Bras, N.M. Cerqueira, M.J. Ramos, P.A. Fernandes Glycosidase inhibitors: a patent review (2008–2013), Expert opinion on therapeutic patents, 24, 857–874 (2014).
315. [315] Osonoi, T., Alpha-glucosidase inhibitor. Nihon Rinsho Jpn. J. Clin. Med. 73 (2015), 390–394.
316. [316] Hoogwerf, B.J., Doshi, K.B., Diab, D., Pramlintide, the synthetic analogue of amylin: physiology, pathophysiology, and effects on glycemic control, body weight, and selected biomarkers of vascular risk. Vasc. Health Risk Manage. 4 (2008), 355–362.
317. [317] Buse, J.B., Weyer, C., Maggs, D.G., Amylin replacement with pramlintide in type 1 and type 2 diabetes: a physiological approach to overcome barriers with insulin therapy. Clin. Diabetes 20 (2002), 137–144.
318. [318] Uwaifo, G.I., Ratner, R.E., Novel pharmacologic agents for type 2 diabetes. Endocrinol. Metab. Clin. North Am. 34 (2005), 155–197.
319. [319] Roberts, A.N., Leighton, B., Todd, J.A., Cockburn, D., Schofield, P.N., Sutton, R., Holt, S., Boyd, Y., Day, A.J., Foot, E.A., et al. Molecular and functional characterization of amylin, a peptide associated with type 2 diabetes mellitus. Proc. Natl. Acad. Sci. U. S. A. 86 (1989), 9662–9666.
320. [320] Adeghate, E., Kalasz, H., Amylin analogues in the treatment of diabetes mellitus: medicinal chemistry and structural basis of its function. Open Med. Chem. J. 5 (2011), 78–81.
321. [321] Valentine, V., Don't resist using U-500 insulin and pramlintide for severe insulin resistance. Clin. Diabetes 30 (2012), 80–84.
322. [322] Fineman, M., Weyer, C., Maggs, D.G., Strobel, S., Kolterman, O.G., The human amylin analog, pramlintide, reduces postprandial hyperglucagonemia in patients with type 2 diabetes mellitus. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 34 (2002), 504–508.
323. [323] Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., Horowitz, M., Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes. Diabetologia 48 (2005), 838–848.
324. [324] Ratner, R.E., Want, L.L., Fineman, M.S., Velte, M.J., Ruggles, J.A., Gottlieb, A., Weyer, C., Kolterman, O.G., Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes. Diabetes Technol. Ther. 4 (2002), 51–61.
325. [325] Wang, H., Abedini, A., Ruzsicska, B., Raleigh, D.P., Rationally designed, nontoxic, nonamyloidogenic analogues of human islet amyloid polypeptide with improved solubility. Biochemistry 53 (2014), 5876–5884.
326. [326] El-Abhar, H.S., Schaalan, M.F., Phytotherapy in diabetes: review on potential mechanistic perspectives. World J. Diabetes 5 (2014), 176–197.
327. [327] Kavishankar, N.L.G.B., Murthy, S.M., Prakash, H.S., Niranjana, S.R., Diabetes and medicinal plants—a review. Int. J. Pharm. Biomed. Sci., 2, 2011.
328. [328] Chawla, R., Thakur, P., Chowdhry, A., Jaiswal, S., Sharma, A., Goel, R., Sharma, J., Priyadarshi, S.S., Kumar, V., Sharma, R.K., Arora, R., Evidence based herbal drug standardization approach in coping with challenges of holistic management of diabetes: a dreadful lifestyle disorder of 21 st century. J. Diabetes Metabol. Disord., 12, 2013, 35.
329. [329] Jang, M., Cai, L., Udeani, G.O., Slowing, K.V., Thomas, C.F., Beecher, C.W., Fong, H.H., Farnsworth, N.R., Kinghorn, A.D., Mehta, R.G., Moon, R.C., Pezzuto, J.M., Cancer chemopreventive activity of resveratrol: a natural product derived from grapes. Science 275 (1997), 218–220.
330. [330] Frombaum, M., Le Clanche, S., Bonnefont-Rousselot, D., Borderie, D., Antioxidant effects of resveratrol and other stilbene derivatives on oxidative stress and NO bioavailability: potential benefits to cardiovascular diseases. Biochimie 94 (2012), 269–276.
331. [331] Zordoky, B.N., Robertson, I.M., Dyck, J.R., Preclinical and clinical evidence for the role of resveratrol in the treatment of cardiovascular diseases. Biochim. Biophys. Acta 1852 (2015), 1155–1177.
332. [332] Carter, L.G., D'Orazio, J.A., Pearson, K.J., Resveratrol and cancer: focus on in vivo evidence. Endocr. Relat. Cancer 21 (2014), R209–R225.
333. [333] Bastianetto, S., Menard, C., Quirion, R., Neuroprotective action of resveratrol. Biochim. Biophys. Acta 1852 (2015), 1195–1201.
334. [334] Dutt, V., Gupta, S., Dabur, R., Injeti, E., Mittal, A., Skeletal muscle atrophy: potential therapeutic agents and their mechanisms of action. Pharmacol. Res. 99 (2015), 86–100.
335. [335] Chen, L.L., Zhang, H.H., Zheng, J., Hu, X., Kong, W., Hu, D., Wang, S.X., Zhang, P., Resveratrol attenuates high-fat diet-induced insulin resistance by influencing skeletal muscle lipid transport and subsarcolemmal mitochondrial beta-oxidation. Metabolism 60 (2011), 1598–1609.
336. [336] Tan, Z., Zhou, L.J., Mu, P.W., Liu, S.P., Chen, S.J., Fu, X.D., Wang, T.H., Caveolin-3 is involved in the protection of resveratrol against high-fat-diet-induced insulin resistance by promoting GLUT4 translocation to the plasma membrane in skeletal muscle of ovariectomized rats. J. Nutr. Biochem. 23 (2012), 1716–1724.
337. [337] Szkudelski, T., Szkudelska, K., Resveratrol and diabetes: from animal to human studies. Biochim. Biophys. Acta 1852 (2015), 1145–1154.
338. [338] Movahed, A., Nabipour, I., Lieben Louis, X., Thandapilly, S.J., Yu, L., Kalantarhormozi, M., Rekabpour, S.J., Netticadan, T., Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid.-Based Complement. Altern. Med.: eCAM., 2013, 2013, 851267.
339. [339] Burgess, T.A., Robich, M.P., Chu, L.M., Bianchi, C., Sellke, F.W., Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch. Surg. 146 (2011), 556–564.
340. [340] Breen, D.M., Sanli, T., Giacca, A., Tsiani, E., Stimulation of muscle cell glucose uptake by resveratrol through sirtuins and AMPK. Biochem. Biophys. Res. Commun. 374 (2008), 117–122.
341. [341] Gledhill, J.R., Montgomery, M.G., Leslie, A.G., Walker, J.E., Mechanism of inhibition of bovine F1-ATPase by resveratrol and related polyphenols. Proc. Natl. Acad. Sci. U. S. A. 104 (2007), 13632–13637.
342. [342] Price, N.L., Gomes, A.P., Ling, A.J., Duarte, F.V., Martin-Montalvo, A., North, B.J., Agarwal, B., Ye, L., Ramadori, G., Teodoro, J.S., Hubbard, B.P., Varela, A.T., Davis, J.G., Varamini, B., Hafner, A., Moaddel, R., Rolo, A.P., Coppari, R., Palmeira, C.M., de Cabo, R., Baur, J.A., Sinclair, D.A., SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 15 (2012), 675–690.
343. [343] Um, J.H., Park, S.J., Kang, H., Yang, S., Foretz, M., McBurney, M.W., Kim, M.K., Viollet, B., Chung, J.H., AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 59 (2010), 554–563.
344. [344] Brasnyo, P., Molnar, G.A., Mohas, M., Marko, L., Laczy, B., Cseh, J., Mikolas, E., Szijarto, I.A., Merei, A., Halmai, R., Meszaros, L.G., Sumegi, B., Wittmann, I., Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106 (2011), 383–389.
345. [345] Kulkarni, S.S., Canto, C., The molecular targets of resveratrol. Biochim. Biophys. Acta 1852 (2015), 1114–1123.
346. [346] Szkudelska, K., Nogowski, L., Szkudelski, T., Resveratrol, a naturally occurring diphenolic compound, affects lipogenesis, lipolysis and the antilipolytic action of insulin in isolated rat adipocytes. J. Steroid Biochem. Mol. Biol. 113 (2009), 17–24.
347. [347] Chen, W.P., Chi, T.C., Chuang, L.M., Su, M.J., Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells. Eur. J. Pharmacol. 568 (2007), 269–277.
348. [348] Leng, S.H., Lu, F.E., Xu, L.J., Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacol. Sin. 25 (2004), 496–502.
349. [349] Turner, N., Li, J.Y., Gosby, A., To, S.W., Cheng, Z., Miyoshi, H., Taketo, M.M., Cooney, G.J., Kraegen, E.W., James, D.E., Hu, L.H., Li, J., Ye, J.M., Berberine and its more biologically available derivative, dihydroberberine, inhibit mitochondrial respiratory complex I: a mechanism for the action of berberine to activate AMP-activated protein kinase and improve insulin action. Diabetes 57 (2008), 1414–1418.
350. [350] Cheng, Z., Pang, T., Gu, M., Gao, A.H., Xie, C.M., Li, J.Y., Nan, F.J., Li, J., Berberine-stimulated glucose uptake in L6 myotubes involves both AMPK and p38 MAPK. Biochim. Biophys. Acta 1760 (2006), 1682–1689.
351. [351] Zhou, L., Yang, Y., Wang, X., Liu, S., Shang, W., Yuan, G., Li, F., Tang, J., Chen, M., Chen, J., Berberine stimulates glucose transport through a mechanism distinct from insulin. Metabolism 56 (2007), 405–412.
352. [352] Zhang, H., Wei, J., Xue, R., Wu, J.D., Zhao, W., Wang, Z.Z., Wang, S.K., Zhou, Z.X., Song, D.Q., Wang, Y.M., Pan, H.N., Kong, W.J., Jiang, J.D., Berberine lowers blood glucose in type 2 diabetes mellitus patients through increasing insulin receptor expression. Metabolism 59 (2010), 285–292.
353. [353] Yan, Z.Q., Leng, S.H., Lu, F.E., Lu, X.H., Dong, H., Gao, Z.Q., Effects of berberine on expression of hepatocyte nuclear factor 4alpha and glucokinase activity in mouse primary hepatocytes. Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica 33 (2008), 2105–2109.
354. [354] Yin, J., Zhang, H., Ye, J., Traditional chinese medicine in treatment of metabolic syndrome. Endocr. Metab. Immune Disord. Drug Targets 8 (2008), 99–111.
355. [355] Huang, C., Zhang, Y., Gong, Z., Sheng, X., Li, Z., Zhang, W., Qin, Y., Berberine inhibits 3T3-L1 adipocyte differentiation through the PPARgamma pathway. Biochem. Biophys. Res. Commun. 348 (2006), 571–578.
356. [356] Choi, B.H., Ahn, I.S., Kim, Y.H., Park, J.W., Lee, S.Y., Hyun, C.K., Do, M.S., Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3-L1 adipocyte. Exp. Mol. Med. 38 (2006), 599–605.
357. [357] Prabhakar, P.K., Doble, M., Effect of natural products on commercial oral antidiabetic drugs in enhancing 2-deoxyglucose uptake by 3T3-L1 adipocytes. Ther. Adv. Endocrinol. Metab. 2 (2011), 103–114.
358. [358] Choi, J., Kim, T.H., Choi, T.Y., Lee, M.S., Ginseng for health care: a systematic review of randomized controlled trials in Korean literature. PLoS One, 8, 2013, e59978.
359. [359] Sotaniemi, E.A., Haapakoski, E., Rautio, A., Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care 18 (1995), 1373–1375.
360. [360] Liu, T.P., Liu, I.M., Cheng, J.T., Improvement of insulin resistance by panax ginseng in fructose-rich chow-fed rats. Hormone and Metabolic Research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 37 (2005), 146–151.
361. [361] Yuan, H.D., Kim, J.T., Kim, S.H., Chung, S.H., Ginseng and diabetes: the evidences from in vitro: animal and human studies. J. Ginseng Res. 36 (2012), 27–39.
362. [362] Wei, S., Li, W., Yu, Y., Yao, F., Lau, A., Lan, X., Guan, F., Zhang, M., Chen, L., Ginsenoside compound K suppresses the hepatic gluconeogenesis via activating adenosine-5'monophosphate kinase: a study in vitro and in vivo. Life Sci. 139 (2015), 8–15.
363. [363] Waki, I., Kyo, H., Yasuda, M., Kimura, M., Effects of a hypoglycemic component of ginseng radix on insulin biosynthesis in normal and diabetic animals. J. Pharmacobiodyn. 5 (1982), 547–554.
364. [364] Rotshteyn, Y., Zito, S.W., Application of modified in vitro screening procedure for identifying herbals possessing sulfonylurea-like activity. J. Ethnopharmacol. 93 (2004), 337–344.
365. [365] Yuan, Z., Liao, Y., Tian, G., Li, H., Jia, Y., Zhang, H., Tan, Z., Li, X., Deng, W., Liu, K., Zhang, Y., Panax notoginseng saponins inhibit Zymosan A induced atherosclerosis by suppressing integrin expression, FAK activation and NF-kappaB translocation. J. Ethnopharmacol. 138 (2011), 150–155.
366. [366] Kim do, Y., Yuan, H.D., Chung, I.K., Chung, S.H., Compound K, intestinal metabolite of ginsenoside, attenuates hepatic lipid accumulation via AMPK activation in human hepatoma cells. J. Agric. Food Chem. 57 (2009), 1532–1537.
367. [367] Lee, H.J., Lee, Y.H., Park, S.K., Kang, E.S., Kim, H.J., Lee, Y.C., Choi, C.S., Park, S.E., Ahn, C.W., Cha, B.S., Lee, K.W., Kim, K.S., Lim, S.K., Lee, H.C., Korean red ginseng (Panax ginseng) improves insulin sensitivity and attenuates the development of diabetes in Otsuka Long-Evans Tokushima fatty rats. Metabolism 58 (2009), 1170–1177.
368. [368] Kim, H.Y., Kim, K., Protective effect of ginseng on cytokine-induced apoptosis in pancreatic beta-cells. J. Agric. Food Chem. 55 (2007), 2816–2823.
369. [369] Chung, S.H., Choi, C.G., Park, S.H., Comparisons between white ginseng radix and rootlet for antidiabetic activity and mechanism in KKAy mice. Arch. Pharmacal Res. 24 (2001), 214–218.
370. [370] Jeong, K.J., Kim, G.W., Chung, S.H., AMP-activated protein kinase: an emerging target for ginseng. J. Ginseng Res. 38 (2014), 83–88.
371. [371] Sheng, X., Zhang, Y., Gong, Z., Huang, C., Zang, Y.Q., Improved insulin resistance and lipid metabolism by cinnamon extract through activation of peroxisome proliferator-Activated receptors. PPAR Res., 2008(581348), 2008.
372. [372] Shen, Y., Honma, N., Kobayashi, K., Jia, L.N., Hosono, T., Shindo, K., Ariga, T., Seki, T., Cinnamon extract enhances glucose uptake in 3T3-L1 adipocytes and C2C12 myocytes by inducing LKB1-AMP-activated protein kinase signaling. PLoS One, 9, 2014, e87894.
373. [373] Shatwan, I.A., Ahmed, L.A., Badkook, M.M., Effect of barley flour, crude cinnamon, and their combination on glycemia, dyslipidemia, and adipose tissue hormones in type 2 diabetic rats. J. Med. Food 16 (2013), 656–662.
374. [374] Kouzi, S.A., Yang, S., Nuzum, D.S., Dirks-Naylor, A.J., Natural supplements for improving insulin sensitivity and glucose uptake in skeletal muscle. Front. Biosci. 7 (2015), 94–106.
375. [375] Medagama, A.B., The glycaemic outcomes of Cinnamon, a review of the experimental evidence and clinical trials. Nutr. J., 14(108), 2015.
376. [376] Jiao, L., Zhang, X., Huang, L., Gong, H., Cheng, B., Sun, Y., Li, Y., Liu, Q., Zheng, L., Huang, K., Proanthocyanidins are the major anti-diabetic components of cinnamon water extract. Food Chem. Toxicol. 56 (2013), 398–405.
377. [377] Li, J., Liu, T., Wang, L., Guo, X., Xu, T., Wu, L., Qin, L., Sun, W., Antihyperglycemic and antihyperlipidemic action of cinnamaldehyde in C57BLKS/J db/db mice. Journal of Traditional Chinese Medicine = Chung i tsa chih ying wen pan/sponsored by All-China Association of Traditional Chinese Medicine Academy of Traditional Chinese Medicine 32 (2012), 446–452.
378. [378] Mirfeizi, M., Mehdizadeh Tourzani, Z., Mirfeizi, S.Z., Asghari Jafarabadi, M., Rezvani, H.R., Afzali, M., Gholami, M.J., Controlling diabetes mellitus type 2 with herbal medicines: a triple blind, randomized clinical trial of efficacy and safety. J. Diabetes 8:5 (2016), 647–656, 10.1111/1753-0407.12342 Epub 2015 Dec 1.
379. [379] Allen, R.W., Schwartzman, E., Baker, W.L., Coleman, C.I., Phung, O.J., Cinnamon use in type 2 diabetes: an updated systematic review and meta-analysis. Ann. Fam. Med. 11 (2013), 452–459.
380. [380] Leachand, M.J., Kumar, S., Cinnamon for diabetes mellitus. Cochrane Database Syst. Rev., CD007170, 2012 (9).
381. [381] Ruda-Kucerova, J., Kotolova, H., Koupy, D., Effectiveness of phytotherapy in supportive treatment of type 2 diabetes mellitus III. Momordica (Momordica charantia). Ceska a Slovenska Farmacie: casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti 64 (2015), 126–132.
382. [382] Cummings, E., Hundal, H.S., Wackerhage, H., Hope, M., Belle, M., Adeghate, E., Singh, J., Momordica charantia fruit juice stimulates glucose and amino acid uptakes in L6 myotubes. Mol. Cell. Biochem. 261 (2004), 99–104.
383. [383] Iseli, T.J., Turner, N., Zeng, X.Y., Cooney, G.J., Kraegen, E.W., Yao, S., Ye, Y., James, D.E., Ye, J.M., Activation of AMPK by bitter melon triterpenoids involves CaMKKbeta. PLoS One, 8, 2013, e62309.
384. [384] Tan, M.J., Ye, J.M., Turner, N., Hohnen-Behrens, C., Ke, C.Q., Tang, C.P., Chen, T., Weiss, H.C., Gesing, E.R., Rowland, A., James, D.E., Ye, Y., Antidiabetic activities of triterpenoids isolated from bitter melon associated with activation of the AMPK pathway. Chem. Biol. 15 (2008), 263–273.
385. [385] Huang, T.N., Lu, K.N., Pai, Y.P., Chin, H., Huang, C.J., Role of GLP-1 in the hypoglycemic effects of wild bitter gourd. Evid.-Based Complement. Altern. Med.: eCAM, 2013, 2013, 625892.
386. [386] Kimand, K., Kim, H.Y., Bitter melon (Momordica charantia) extract suppresses cytokineinduced activation of MAPK and NF-κB in pancreatic β-Cells. Food Sci. Biotechnol. 20 (2011), 531–535.
387. [387] Gadang, V., Gilbert, W., Hettiararchchy, N., Horax, R., Katwa, L., Devareddy, L., Dietary bitter melon seed increases peroxisome proliferator-activated receptor-gamma gene expression in adipose tissue, down-regulates the nuclear factor-kappaB expression, and alleviates the symptoms associated with metabolic syndrome. J. Med. Food 14 (2011), 86–93.
388. [388] Shibib, B.A., Khan, L.A., Rahman, R., Hypoglycaemic activity of Coccinia indica and Momordica charantia in diabetic rats: depression of the hepatic gluconeogenic enzymes glucose-6-phosphatase and fructose-1,6-bisphosphatase and elevation of both liver and red-cell shunt enzyme glucose-6-phosphate dehydrogenase. Biochem. J. 292:Pt. 1 (1993), 267–270.
389. [389] Singh, J., Cumming, E., Manoharan, G., Kalasz, H., Adeghate, E., Medicinal chemistry of the anti-diabetic effects of momordica charantia: active constituents and modes of actions. Open Med. Chem. J. 5 (2011), 70–77.
390. [390] Lo, H.Y., Ho, T.Y., Li, C.C., Chen, J.C., Liu, J.J., Hsiang, C.Y., A novel insulin receptor-binding protein from Momordica charantia enhances glucose uptake and glucose clearance in vitro and in vivo through triggering insulin receptor signaling pathway. J. Agric. Food Chem. 62 (2014), 8952–8961.
391. [391] Jayasooriya, A.P., Sakono, M., Yukizaki, C., Kawano, M., Yamamoto, K., Fukuda, N., Effects of Momordica charantia powder on serum glucose levels and various lipid parameters in rats fed with cholesterol-free and cholesterol-enriched diets. J. Ethnopharmacol. 72 (2000), 331–336.
392. [392] Inayat, U.R., Khan, R.U., Khalil Ur, R., Bashir, M., Lower hypoglycemic but higher antiatherogenic effects of bitter melon than glibenclamide in type 2 diabetic patients. Nutr. J., 14, 2015, 13.
393. [393] Yin, R.V., Lee, N.C., Hirpara, H., Phung, O.J., The effect of bitter melon (Mormordica charantia) in patients with diabetes mellitus: a systematic review and meta-analysis. Nutr. Diabetes, 4, 2014, e145.
394. [394] Leduc, C., Coonishish, J., Haddad, P., Cuerrier, A., Plants used by the Cree Nation of Eeyou Istchee (Quebec, Canada) for the treatment of diabetes: a novel approach in quantitative ethnobotany. J. Ethnopharmacol. 105 (2006), 55–63.
395. [395] Eid, H.M., Haddad, P.S., Mechanisms of action of indigenous antidiabetic plants from the boreal forest of northeastern Canada. Adv. Endocrinol., 2014, 2014, 11.
396. [396] Miura, T., Takagi, S., Ishida, T., Management of diabetes and its complications with banaba (Lagerstroemia speciosa L.) and corosolic acid. Evid.-Based Complement. Altern. Med.: eCAM, 2012, 2012, 871495.
397. [397] Liu, F., Kim, J., Li, Y., Liu, X., Li, J., Chen, X., An extract of Lagerstroemia speciosa L. has insulin-like glucose uptake-stimulatory and adipocyte differentiation-inhibitory activities in 3T3-L1 cells. J. Nutr. 131 (2001), 2242–2247.
398. [398] Liu, X., Kim, J.K., Li, Y., Li, J., Liu, F., Chen, X., Tannic acid stimulates glucose transport and inhibits adipocyte differentiation in 3T3-L1 cells. J. Nutr. 135 (2005), 165–171.
399. [399] Miura, T., Itoh, Y., Kaneko, T., Ueda, N., Ishida, T., Fukushima, M., Matsuyama, F., Seino, Y., Corosolic acid induces GLUT4 translocation in genetically type 2 diabetic mice. Biol. Pharm. Bull. 27 (2004), 1103–1105.
400. [400] Yamada, K., Hosokawa, M., Fujimoto, S., Fujiwara, H., Fujita, Y., Harada, N., Yamada, C., Fukushima, M., Ueda, N., Kaneko, T., Matsuyama, F., Yamada, Y., Seino, Y., Inagaki, N., Effect of corosolic acid on gluconeogenesis in rat liver. Diabetes Res. Clin. Pract. 80 (2008), 48–55.
401. [401] Keawpradub, N., Purintrapiban, J., Upregulation of glucose uptake in L8 myotubes by the extract from Lagerstroemia speciosa: a possible mechanism of action. Maejo Int. J. Sci. Technol. 3:03 (2009), 472–485.
402. [402] Hattori, K., Sukenobu, N., Sasaki, T., Takasuga, S., Hayashi, T., Kasai, R., Yamasaki, K., Hazeki, O., Activation of insulin receptors by lagerstroemin. J. Pharmacol. Sci. 93 (2003), 69–73.
403. [403] Elya, B., Handayani, R., Sauriasari, R., Azizahwati, U.S., Hasyyati Permana, I.T., Permatasari, Y.I., Antidiabetic activity and phytochemical screening of extracts from indonesian plants by inhibition of alpha amylase, alpha glucosidase and dipeptidyl peptidase IV. Pak J. Biol. Sci. 18 (2015), 279–284.
404. [404] Ichikawa, H., Yagi, H., Tanaka, T., Cyong, J.C., Masaki, T., Lagerstroemia speciosa extract inhibit TNF-induced activation of nuclear factor-kappaB in rat cardiomyocyte H9c2 cells. J. Ethnopharmacol. 128 (2010), 254–256.
405. [405] Saumya, S.M., Basha, P.M., Antioxidant effect of Lagerstroemia speciosa Pers (banaba) leaf extract in streptozotocin-induced diabetic mice. Indian J. Exp. Biol. 49 (2011), 125–131.
406. [406] Saxena, A., Vikram, N.K., Role of selected Indian plants in management of type 2 diabetes: a review. J. Altern. Complement. Med. 10 (2004), 369–378.
407. [407] Maurya, C.K., Singh, R., Jaiswal, N., Venkateswarlu, K., Narender, T., Tamrakar, A.K., 4-Hydroxyisoleucine ameliorates fatty acid-induced insulin resistance and inflammatory response in skeletal muscle cells. Mol. Cell. Endocrinol. 395 (2014), 51–60.
408. [408] Kalailingam, P., Kannaian, B., Tamilmani, E., Kaliaperumal, R., Efficacy of natural diosgenin on cardiovascular risk, insulin secretion, and beta cells in streptozotocin (STZ)-induced diabetic rats. Phytomed.: Int. J. Phytother. Phytopharmacol. 21 (2014), 1154–1161.
409. [409] Fuller, S., Stephens, J.M., Diosgenin, 4-hydroxyisoleucine, and fiber from fenugreek: mechanisms of actions and potential effects on metabolic syndrome. Adv. Nutr. 6 (2015), 189–197.
410. [410] King, K., Lin, N.P., Cheng, Y.H., Chen, G.H., Chein, R.J., Isolation of positive modulator of glucagon-like peptide-1 signaling from trigonella foenum-graecum (Fenugreek) seed. J. Biol. Chem. 290 (2015), 26235–26248.
411. [411] Puri, D., Prabhu, K.M., Dev, G., Agarwal, S., Murthy, P.S., Mechanism of antidiabetic action of compound GII purified from fenugreek (Trigonella foenum graecum) seeds. Indian J. Clin. Biochem. 26 (2011), 335–346.
412. [412] Sharma, R., Amin, H., Galib, Prajapati, P.K., Antidiabetic claims of Tinospora cordifolia (Willd.) Miers: critical appraisal and role in therapy. Asian Pac. J. Trop. Biomed. 5 (2015), 68–78.
413. [413] Sudha, P., Zinjarde, S.S., Bhargava, S.Y., Kumar, A.R., Potent alpha-amylase inhibitory activity of Indian Ayurvedic medicinal plants. BMC Complement. Altern. Med., 11, 2011, 5.
414. [414] Pandey, M., Surendra, K., Chikara, M.K.V., Rohit, S., Thakur, S.G., Tinospora cordifolia: a climbing shrub in health care management. Int. J. Pharm. Biol. Sci. 3 (2012), 612–628.
415. [415] Singh, S.S., Pandey, S.C., Srivastava, S., Gupta, V.S., Patro, B., Chemistry and medicinal properties of tinospora cordifolia (guduchi). Indian J. Pharmacol. 35 (2003), 83–91.
416. [416] Patel, M.B., Mishra, S., Hypoglycemic activity of alkaloidal fraction of Tinospora cordifolia. Phytomed.: Int. J. Phytother. Phytopharmacol. 18 (2011), 1045–1052.
417. [417] Sangeetha, M.K., Priya, C.D., Vasanthi, H.R., Anti-diabetic property of Tinospora cordifolia and its active compound is mediated through the expression of Glut-4 in L6 myotubes. Phytomed.: Int. J. Phytother. Phytopharmacol. 20 (2013), 246–248.
418. [418] Sivakumar, V., Rajan, M.S., Antioxidant effect of tinospora cordifolia extract in alloxan-induced diabetic rats. Indian J. Pharm. Sci. 72 (2010), 795–798.
419. [419] Kalekar, S.A., Munshi, R.P., Bhalerao, S.S., Thatte, U.M., Insulin sensitizing effect of 3 Indian medicinal plants: an in vitro study. Indian J. Pharmacol. 45 (2013), 30–33.
420. [420] Grover, J.K., Vats, V., Rathi, S.S., Anti-hyperglycemic effect of Eugenia jambolana and Tinospora cordifolia in experimental diabetes and their effects on key metabolic enzymes involved in carbohydrate metabolism. J. Ethnopharmacol. 73 (2000), 461–470.
421. [421] Reddy, S.S., Ramatholisamma, P., Karuna, R., Saralakumari, D., Preventive effect of Tinospora cordifolia against high-fructose diet-induced insulin resistance and oxidative stress in male Wistar rats. Food Chem. Toxicol. 47 (2009), 2224–2229.
422. [422] Sangeetha, M.K., Balaji Raghavendran, H.R., Gayathri, V., Vasanthi, H.R., Tinospora cordifolia attenuates oxidative stress and distorted carbohydrate metabolism in experimentally induced type 2 diabetes in rats. J. Nat. Med. 65 (2011), 544–550.
423. [423] Sengupta, S., Mukherjee, A., Goswami, R., Basu, S., Hypoglycemic activity of the antioxidant saponarin, characterized as alpha-glucosidase inhibitor present in Tinospora cordifolia. J. Enzyme Inhib. Med. Chem. 24 (2009), 684–690.
424. [424] Stanely Mainzen Prince, P., Menon, V.P., Gunasekaran, G., Hypolipidaemic action of Tinospora cordifolia roots in alloxan diabetic rats. J. Ethnopharmacol. 64 (1999), 53–57.
425. [425] Karkal, Y.R., Bairy, L.K., Safety of aqueous extract of Tinospora cordifolia (Tc) in healthy volunteers: a double blind randomised placebo controlled study. Iran. J. Pharmacol. Ther. 6 (2007), 59–61.
426. [426] Sai, K.S., Srividya, N., Blood glucose lowering effect of the leaves of Tinospora cordifolia and Sauropus androgynus in diabetic subjects. J. Nat. Remedies 2 (2002), 28–32.
427. [427] Noorand, H., Ashcroft, S.J., Pharmacological characterisation of the antihyperglycaemic properties of Tinospora crispa extract. J. Ethnopharmacol. 62 (1998), 7–13.
428. [428] Ruan, C.T., Lam, S.H., Chi, T.C., Lee, S.S., Su, M.J., Borapetoside C from Tinospora crispa improves insulin sensitivity in diabetic mice. Phytomed.: Int. J. Phytother. Phytopharmacol. 19 (2012), 719–724.
429. [429] Ahmad, W., Jantan, I., Bukhari, S.N., Tinospora crispa (L.) Hook. f. & Thomson: a review of its ethnobotanical, phytochemical, and pharmacological aspects. Front. Pharmacol., 7(59), 2016.
430. [430] Hamidpour, M., Hamidpour, R., Hamidpour, S., Shahlari, M., Chemistry, pharmacology, and medicinal property of sage (Salvia) to prevent and cure illnesses such as obesity, diabetes, depression, dementia, lupus, autism, heart disease, and cancer. J. Tradit. Complement. Med. 4 (2014), 82–88.
431. [431] Eidi, M., Eidi, A., Zamanizadeh, H., Effect of Salvia officinalis L. leaves on serum glucose and insulin in healthy and streptozotocin-induced diabetic rats. J. Ethnopharmacol. 100 (2005), 310–313.
432. [432] Christensen, K.B., Jorgensen, M., Kotowska, D., Petersen, R.K., Kristiansen, K., Christensen, L.P., Activation of the nuclear receptor PPARgamma by metabolites isolated from sage (Salvia officinalis L.). J. Ethnopharmacol. 132 (2010), 127–133.
433. [433] Kianbakht, S., Dabaghian, F.H., Improved glycemic control and lipid profile in hyperlipidemic type 2 diabetic patients consuming Salvia officinalis L. leaf extract: a randomized placebo. Controlled clinical trial. Complement. Ther. Med. 21 (2013), 441–446.
434. [434] Paddy, V., van Tonder, J.J., Steenkamp, V., In vitro antidiabetic activity of a polyherbal tea and its individual ingredients. Br. J. Pharm. Res. 6 (2015), 389–401.
435. [435] Lima, C.F., Azevedo, M.F., Araujo, R., Fernandes-Ferreira, M., Pereira-Wilson, C., Metformin-like effect of Salvia officinalis (common sage): is it useful in diabetes prevention?. Br. J. Nutr. 96 (2006), 326–333.
436. [436] Moradabadi, L., Montasser Kouhsari, S., Fehresti Sani, M., Hypoglycemic effects of three medicinal plants in experimental diabetes: inhibition of rat intestinal alpha-glucosidase and enhanced pancreatic insulin and cardiac glut-4 mRNAs expression. Iran. J. Pharm. Res. IJPR 12 (2013), 387–397.
437. [437] Behradmanesh, S., Derees, F., Rafieian-Kopaei, M., Effect of Salvia officinalis on diabetic patients. J. Renal Injury Prev. 2 (2013), 51–54.
438. [438] Fotino, N., Fotino, C., Pileggi, A., Re-engineering islet cell transplantation. Pharmacol. Res. 98 (2015), 76–85.
439. [439] Usuelli, V., Rocca, E. La, Novel therapeutic approaches for diabetic nephropathy and retinopathy. Pharmacol. Res. 98 (2015), 39–44.
440. [440] Watson, C.J., The current challenges for pancreas transplantation for diabetes mellitus. Pharmacol. Res. 98 (2015), 45–51.
441. [441] Deiuliis, J.A., MicroRNAs as regulators of metabolic disease: pathophysiologic significance and emerging role as biomarkers and therapeutics. Int. J. Obes., 2015.
442. [442] Wang, Z., Shang, J., Xia, W., Targets and candidate agents for type 2 diabetes treatment with computational bioinformatics approach. J. Diabetes Res., 2014(763936), 2014.
443. [443] Kumar, M., Nath, S., Prasad, H.K., Sharma, G.D., Li, Y., MicroRNAs: a new ray of hope for diabetes mellitus. Protein Cell 3 (2012), 726–738.
444. [444] Chien, H.Y., Lee, T.P., Chen, C.Y., Chiu, Y.H., Lin, Y.C., Lee, L.S., Li, W.C., Circulating microRNA as a diagnostic marker in populations with type 2 diabetes mellitus and diabetic complications. J. Chin. Med. Assoc.: JCMA. 78 (2015), 204–211.
445. [445] Wang, L., Zhang, N., Pan, H.P., Wang, Z., Cao, Z.Y., MiR-499-5p contributes to hepatic insulin resistance by suppressing PTEN. Cell. Physiol. Biochem. 36 (2015), 2357–2365.
446. [446] Zhao, H., Guan, J., Lee, H.M., Sui, Y., He, L., Siu, J.J., Tse, P.P., Tong, P.C., Lai, F.M., Chan, J.C., Up-regulated pancreatic tissue microRNA-375 associates with human type 2 diabetes through beta-cell deficit and islet amyloid deposition. Pancreas 39 (2010), 843–846.
447. [447] Karolina, D.S., Armugam, A., Tavintharan, S., Wong, M.T., Lim, S.C., Sum, C.F., Jeyaseelan, K., MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One, 6, 2011, e22839.
448. [448] Yan, S.T., Li, C.L., Tian, H., Li, J., Pei, Y., Liu, Y., Gong, Y.P., Fang, F.S., Sun, B.R., MiR-199a is overexpressed in plasma of type 2 diabetes patients which contributes to type 2 diabetes by targeting GLUT4. Mol. Cell. Biochem. 397 (2014), 45–51.
449. [449] Fu, X., Dong, B., Tian, Y., Lefebvre, P., Meng, Z., Wang, X., Pattou, F., Han, W., Wang, X., Lou, F., Jove, R., Staels, B., Moore, D.D., Huang, W., MicroRNA-26a regulates insulin sensitivity and metabolism of glucose and lipids. J. Clin. Invest. 125 (2015), 2497–2509.
450. [450] Zhou, B., Li, C., Qi, W., Zhang, Y., Zhang, F., Wu, J.X., Hu, Y.N., Wu, D.M., Liu, Y., Yan, T.T., Jing, Q., Liu, M.F., Zhai, Q.W., Downregulation of miR-181a upregulates sirtuin-1 (SIRT1) and improves hepatic insulin sensitivity. Diabetologia 55 (2012), 2032–2043.
451. [451] Lu, H., Buchan, R.J., Cook, S.A., MicroRNA-223 regulates Glut4 expression and cardiomyocyte glucose metabolism. Cardiovasc. Res. 86 (2010), 410–420.
452. [452] Al-Kafaji, G., Al-Mahroos, G., Alsayed, N.A., Hasan, Z.A., Nawaz, S., Bakhiet, M., Peripheral blood microRNA-15a is a potential biomarker for type 2 diabetes mellitus and pre-diabetes. Mol. Med. Rep. 12 (2015), 7485–7490.
453. [453] Yang, Z., Chen, H., Si, H., Li, X., Ding, X., Sheng, Q., Chen, P., Zhang, H., Serum miR-23a, a potential biomarker for diagnosis of pre-diabetes and type 2 diabetes. Acta Diabetol. 51 (2014), 823–831.
454. [454] Pescador, N., Perez-Barba, M., Ibarra, J.M., Corbaton, A., Martinez-Larrad, M.T., Serrano-Rios, M., Serum circulating microRNA profiling for identification of potential type 2 diabetes and obesity biomarkers. PLoS One, 8, 2013, e77251.
455. [455] Parrizas, M., Brugnara, L., Esteban, Y., Gonzalez-Franquesa, A., Canivell, S., Murillo, S., Gordillo-Bastidas, E., Cusso, R., Cadefau, J.A., Garcia-Roves, P.M., Servitja, J.M., Novials, A., Circulating miR-192 and miR-193b are markers of prediabetes and are modulated by an exercise intervention. J. Clin. Endocrinol. Metab. 100 (2015), E407–415.
456. [456] Kaur, R., Afzal, M., Kazmi, I., Ahamd, I., Ahmed, Z., Ali, B., Ahmad, S., Anwar, F., Polypharmacy (herbal and synthetic drug combination): a novel approach in the treatment of type-2 diabetes and its complications in rats. J. Nat. Med. 67 (2013), 662–671.
457. [457] Rios, J.L., Francini, F., Schinella, G.R., Natural products for the treatment of type 2 diabetes mellitus. Planta Med. 81 (2015), 975–994.
458. [458] Cetrone, M., Mele, A., Tricarico, D., Effects of the antidiabetic drugs on the age-related atrophy and sarcopenia associated with diabetes type II. Curr. Diabetes Rev. 10 (2014), 231–237.